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The increasing burden of major depressive disorder makes the search for an extended
understanding of etiology, and for the development of additional treatments highly signifi-
cant. Biological factors may be useful biomarkers for treatment with physical activity (PA),
and neurobiological effects of PA may herald new therapeutic development in the future.
This paper provides a thorough and up-to-date review of studies examining the neuroim-
munomodulatory effects of PA on the brain in depression and depression-like behaviors.
From a neuroimmune perspective, evidence suggests PA does enhance the beneficial and
reduce the detrimental effects of the neuroimmune system. PA appears to increase the
following factors: interleukin (IL)-10, IL-6 (acutely), macrophage migration inhibitory factor,
central nervous system-specific autoreactive CD4+T cells, M2 microglia, quiescent astro-
cytes, CX3CL1, and insulin-like growth factor-1. On the other hand, PA appears to reduce
detrimental neuroimmune factors such as: Th1/Th2 balance, pro-inflammatory cytokines,
C-reactive protein, M1 microglia, and reactive astrocytes.The effect of other mechanisms is
unknown, such as: CD4+CD25+T regulatory cells (T regs), CD200, chemokines, miRNA,
M2-type blood-derived macrophages, and tumor necrosis factor (TNF)-α [via receptor 2
(R2)]. The beneficial effects of PA are likely to occur centrally and peripherally (e.g., in vis-
ceral fat reduction).The investigation of the neuroimmune effects of PA on depression and
depression-like behavior is a rapidly developing and important field.
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The increasing burden of major depressive disorder (MDD; WHO,
2008) makes the search for an extended understanding of eti-
ology, and for the development of additional treatments highly
significant. The global “pandemic” of physical inactivity (Lee
et al., 2012) – a significant etiological factor for many non-
communicable diseases, including depression (Garber et al., 2011;
Kohl et al., 2012; Lee et al., 2012) – as well as the growing evidence
supporting the clinical utility of physical activity (PA) in many
psychiatric disorders, make the biological effects of PA highly rel-
evant (Knochel et al., 2012; Lautenschlager et al., 2012; Rimer
et al., 2012). Biological factors may be useful biomarkers for treat-
ment with PA, and neurobiological effects of PA may herald new
therapeutic developments in the future.
The neuroimmune system is important in the pathogenesis and
pathophysiology of depression-like behaviors (Eyre and Baune,
2012c). Elevations in pro-inflammatory cytokines (PICs), causing
neuroinflammation, are well known to be involved in the devel-
opment of depression-like behaviors – e.g., sickness-like behavior,
cognitive dysfunction, and anhedonia – in pre-clinical and clini-
cal populations (Dantzer et al., 2008; McAfoose and Baune, 2009;
Miller et al., 2009). The involvement of PICs in the development of
depression-like behavior is often referred to as the cytokine model
of depression (Dantzer et al., 2008; McAfoose and Baune, 2009;
Miller et al., 2009).The neuroinflammatory state is associated
with neurotransmitter dysfunction [e.g., reductions in serotonin
(5-HT), as well as neurotoxic levels of glutamate (GLU) and tryp-
tophan catabolites], reduced hippocampal (HC) neuroplasticity
[e.g., neurogenesis, synaptic plasticity, and long-term potentiation
(LTP)], oxidative stress, and glucocorticoid insensitivity (Dantzer
et al., 2008; Miller et al., 2009; Eyre and Baune, 2012c; Leonard
and Maes, 2012; Moylan et al., 2012).
A variety of novel neuroimmune mechanisms may also be
involved in the development of depression-like behaviors (Eyre
and Baune, 2012c; Littrell, 2012). Cellular immune factors include
various T cells [e.g., CD4+CD25+ T regulatory cells (T regs),
CNS-specific autoreactive CD4+ T cells] and macrophages (e.g.,
M2-type blood-derived macrophages) involved in the model of
protective immunosurveillance (Schwartz and Shechter, 2010a,b;
Martino et al., 2011; Ron-Harel et al., 2011). These neuroprotective
immune cells – found to release neurotrophic factors and anti-
inflammatory cytokines (AICs; Schwartz and Shechter, 2010a,b;
Martino et al., 2011; Ron-Harel et al., 2011) – may be dysfunctional
in the disease state (Schwartz and Shechter, 2010b). Moreover, the
function of immunomodulatory proteins such as CX3CL1 (aka
fractalkine; Rogers et al., 2011; Corona et al., 2012; Giunti et al.,
2012), insulin-like growth factor-1 (IGF-1; Park et al., 2011a), and
CD 200 (Lyons et al., 2007; Ojo et al., 2012) may be reduced.
In clinical studies, PA has shown efficacy in the treatment of
MDD (Rimer et al., 2012), schizophrenia (SCZ; Knochel et al.,
2012), anxiety-based disorders (Asmundson et al., 2013), and in
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enhancing cognitive function in disorders of cognitive function
(i.e.,Alzheimer’s disease,AD and mild cognitive impairment, MCI;
Foster et al., 2011; Knochel et al., 2012; Lautenschlager et al., 2012).
There are many reasons why PA is an attractive therapeutic option
in psychiatry. It has a low side-effect profile and can be adapted
according to a patient’s medical co-morbidities and functional sta-
tus (Garber et al., 2011; Knochel et al., 2012; Rimer et al., 2012). PA
also enhances self-esteem (Salmon, 2001), has less stigmatization
than psychotherapy, may reduce the use of pharmacotherapies in
MDD (Deslandes et al., 2010) and has a positive effect on cardio-
metabolic risk factors relevant to many psychiatric diseases (e.g.,
chronic inflammation, visceral fat mass, glucocorticoid sensitivity,
glucose control, and insulin sensitivity; Gleeson et al., 2011; Baune
et al., 2012c; Hamer et al., 2012; Knochel et al., 2012; Stuart and
Baune, 2012).
Physical activity has beneficial effects on depressive symptoma-
tology in a variety of clinical contexts. It is found to have robust
effects on the depressive phenotype found in MDD (Rimer et al.,
2012), as well as beneficial effects on the depressive symptoma-
tology involved in the negative symptoms of SCZ (Knochel et al.,
2012). PA has also been shown to be effective in treating cognitive
dysfunction-related depression (Knochel et al., 2012; i.e., in MCI
and AD where a significant proportion of patients with AD suffer
from co-morbid depression; Lee and Lyketsos, 2003). The clinical
utility of PA in MDD is promising given most patients on anti-
depressants will not achieve remission following initial treatment
(Trivedi et al., 2006), and nearly one-third will not achieve remis-
sion even following several treatment steps (Rush et al., 2006a,b).
Encouragingly, a recent Cochrane meta-analysis of 28 trials (1101
participants) by Rimer et al. (2012) – comparing exercise with
no treatment or control intervention – found a moderate clinical
effect in MDD. Studies have found that whilst PA has an initial
treatment effect equal to that of antidepressants (Rimer et al.,
2012), its effects are slower (Blumenthal et al., 1999) with greater
relapse prevention (Babyak et al., 2000). PA interventions have
been shown to be efficacious as a stand-alone (Rethorst et al.,
2009) and as an augmentation treatment for MDD (Trivedi et al.,
2011). Adequate levels of PA are also found to have a role in the
prevention of MDD (Pasco et al., 2011b).
Physical activity interventions are found to have a multitude
of effects on neuroimmune processes (Eyre and Baune, 2012a).
Most notably PA interventions are found to reduce PIC levels in
the brain of rodents (Eyre and Baune, 2012a) and in the periph-
ery in clinical studies (Beavers et al., 2010a; Rethorst et al., 2012).
The anti-inflammatory effects of PA may be related to acute eleva-
tions in neuroprotective interleukin-6 (IL-6; Funk et al., 2011), and
resultant downstream changes, e.g., increased IL-1ra and reduced
neuronal death in the HC (Funk et al., 2011). Reductions in
pro-inflammatory visceral fat mass may also play a role in the
anti-inflammatory effect of PA (Gleeson et al., 2011).
The neuroimmune effects of PA were recently outlined in
our review (Eyre and Baune, 2012a), however, there have been
a large number of studies published in 2012 investigating other
neuroimmune-related factors (Moon et al., 2012; Rethorst et al.,
2012). Novel factors investigated include macrophage migration
inhibitor factor (MIF; Moon et al., 2012), CX3CL1 (Vukovic et al.,
2012), and IGF-1 (Duman et al., 2009). Taken together, there is a
need for a review outlining and summarizing these recent stud-
ies in light of pre-existing literature with the intention of better
understanding the neuroimmunological effects of PA. From this
literature important questions arise: Are there PA types which are
more effective than others? Are there subpopulations of patients with
MDD who would benefit more from PA than antidepressants or psy-
chotherapy? Can the neuroimmune effects of PA inform therapeutic
development in the future? Are immune biomarkers potentially useful
in measuring a treatment effect for PA in depression?
This paper provides a thorough and up-to-date review of stud-
ies examining the neuroimmunomodulatory effects of PA on the
brain in depression and depression-like behaviors.
METHODS
This review utilized an electronic search of databases such as
PubMed, PsychInfo, OvidSP, and Science Direct. An initial search
was conducted using the following keywords: (PA OR exer-
cise) AND (immune OR inflammation OR cytokine OR anti-
inflammatory OR immune cell OR glia OR neuroplasticity)
AND/OR depression. Abstracts were selected based on the year
of publication (between 1995 and December 2012), publication
in the English language and of peer-reviewed type. They were
excluded if they included anecdotal evidence. A total of 16,000
studies were found using these search terms. A total of 1000 articles
remained after assessment of abstracts for relevance to the aims of
this review. Of these, 770 studies were excluded after review of the
full text if they did not examine the effect of the PA or depression
on the immune system. A proportion of papers were found via
the reference lists of the 1000 full text articles. Finally, 230 articles
were utilized in this review.
CLINICAL EFFICACY OF PHYSICAL ACTIVITY IN DEPRESSION
Evidence supporting the clinical efficacy of PA interventions with
depression – and depression co-morbid with other diseases [MCI,
coronary heart disease (CHD)] – is growing (Blumenthal et al.,
2012a,b; Rimer et al., 2012). In the clinical setting, exercise inter-
ventions are defined as “planned, structured, and repetitive bodily
movements done to improve or maintain one or more compo-
nents of physical fitness” (Garber et al., 2011). Exercise types can
include aerobic, resistance, neuromotor (involving balance, agility,
and co-ordination), and flexibility types (Garber et al., 2011). The
following section will outline clinical evidence supporting the use
of exercise in depression.
A 2012 re-analysis of available clinical trials by the Cochrane
Group (Rimer et al., 2012; 2009 version; Mead et al., 2008) revealed
28 trials (1101 participants) comparing exercise with no treat-
ment or control intervention finding a moderate clinical effect
in MDD (standardized mean difference, SMD; −0.67 95% CI
−0.90 to−0.43). However, when the meta-analysis was conducted
with more strict criteria – i.e., studies with adequate allocation
concealment, intention-to-treat analysis, and blinded outcome
assessment – there were only four trials (326 participants), the
SMD indicated a small clinical effect (SMD −0.31 95% CI −0.63
to 0.01). Moreover, data from the seven trials (373 participants)
that provided long-term follow-up also found a small effect for
exercise interventions (SMD −0.39, 95% CI −0.69 to −0.09).
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In comparison to cognitive behavioral therapy, six trials (152
participants) found no significant difference with exercise.
Further investigating the individual clinical trials analyzed in
this field yields interesting information on the clinical effect of
exercise regimens. A 16-week randomized controlled trial (RCT)
study by Blumenthal et al. (1999) found aerobic exercise and anti-
depressant (sertraline) treatment were equally effective in reducing
depressive symptom severity [as per both Hamilton Depression
Rating Scale (HAM-D) and Beck Depression Inventory (BDI)],
however, sertaline had a faster initial response (in the first 3 weeks).
Shortly after, a paper by Babyak et al. (2000) was published on
the same study participants showing – at 6 months follow-up –
patients assigned to the exercise program were less likely to relapse
(no longer diagnostic for MDD or HAM-D< 8) than patients
assigned to antidepressant treatment. Self-initiated exercise after
the study intervention was associated with a reduced probability
of depression at the end of the follow-up period (OR= 0.49).
Treatment of depression in older people is often hampered by
poor recognition and increased prevalence of medication side-
effects, polypharmacy, and poor adherence to treatment; therefore,
exercise is increasingly being evaluated as a possible treatment. A
recent meta-analysis (Bridle et al., 2012) of seven trials of subjects
≥60 years found exercise was associated with significantly lower
depression severity (SMD−0.34; 95% CI−0.52 to−0.17). These
findings were irrespective of whether participant eligibility was
determined by clinical diagnosis or symptom checklist. An RCT in
elderly patients (>60 years) with MDD – non-responders to esci-
talopram – found a 10-week Tai Chi Chih (TCC) exercise interven-
tion augmented antidepressant treatment (Lavretsky et al., 2011).
TCC exercise was chosen given it can be readily implemented
among older adults with physical limitations (due to chronic med-
ical illnesses or poor balance) and its added stress reduction and
mindful cognitive properties. Multiple studies have shown regular,
moderate PA can have a positive influence on depressive symp-
tomatology in subjects with AD (Knochel et al., 2012), however
Mahendra and Arkin (2003) found this beneficial effect was only
significant after >1 year of PA. Deslandes et al. (2010) reported
patients with co-morbid MCI and MDD could significantly reduce
their antidepressant dose when they underwent a PA program.
Exercise is shown to have some modest beneficial effects on
certain aspects of neurocognitive disturbance in depression. An
RCT study with patients who met MDD criteria found exercise
(both supervised and home-based) performed better with exercise
than sertraline on tests of executive functioning, but not on tests
of verbal and working memory (Hoffman et al., 2008). A recent
meta-analysis (Smith et al., 2010) examining the effects of aerobic
exercise on neurocognitive performance found 29 studies (2049
participants) showing modest improvements in attention and pro-
cessing speed (g = 0.158; 95% CI, 0.055–0.260), executive function
(g = 0.123; 95% CI, 0.021–0.225), and memory (g = 0.128; 95%
CI, 0.015–0.241).
Depression is a common co-morbidity with a variety of car-
diac conditions. Depression affects as many as 40% of patients
with heart failure (HF), with up to 75% of patients reporting
elevated depressive symptoms (Blumenthal et al., 2012a). For
CHD, MDD affects 15–20% of cardiac patients and an additional
20% report elevated depressive symptoms (Blumenthal et al.,
2012b). Blumenthal et al. (2012a) recently published an RCT of
2322 stable HF patients who underwent an aerobic exercise pro-
gram (supervised for 1–3 months followed by home exercise for
9 months) or education and usual guideline-based HF care. Com-
pared with usual care, aerobic exercise resulted in lower mean
BDI-II scores at 3 and 12 months (differences of−0.76 and−0.68,
respectively). Another study by Blumenthal et al. (2012b) assessed
efficacy of 4 months of aerobic exercise and antidepressant treat-
ments (sertraline) in reducing depressive symptoms and improv-
ing cardiovascular biomarkers in depressed patients with CHD. At
4 months, exercise and sertraline were equally as effective at reduc-
ing depressive symptoms (HRSD) vs. placebo. Exercise tended to
result in greater reductions in heart rate variability vs. sertraline.
When considering the anti-depressive effects of exercise – in
addition to biological effects – we must consider psychosocial
aspects. Studies have shown exercise regimens have a distraction
effect (from negative thoughts and ruminations), provide a sense
of mastery via the learning of new skills (Lepore, 1997), and hence
enhance self-efficacy (Craft, 2005) and self-esteem (Salmon, 2001).
A study by Craft (2005) found that those who experienced an
increase in mood following exercise showed higher self-efficacy
levels at 3 and 9 weeks post-exercise. Self-esteem is considered to be
one of the strongest predictors of overall (Diener, 1984), subjective
well-being and low self-esteem is considered to be closely related
with mental illness (Fox, 2000). The abovementioned beneficial
psychological effects may lead to the stress reducing and stress-
resilience enhancing effects of exercise (Salmon, 2001). Addition-
ally, exercise regimens in a group setting may have a beneficial
effect via training social skill deficits (Rimer et al., 2012).There-
fore, considering the immunomodulatory effects of social support,
i.e., social isolation stress is repeatedly shown to enhance inflam-
mation in clinical and pre-clinical models (Hafner et al., 2011), the
social interaction effects of PA interventions must be considered
as a confounder.
Whilst the vast majority of research using PA in psychiatry is
positive and encouraging, it is important to also consider poten-
tial pre-cautions during PA interventions. Some studies report
no effect for PA in depression (Rimer et al., 2012). This may be
explained by inappropriate intensity of PA, or a too short dura-
tion of PA as a treatment (Rimer et al., 2012). In order to enhance
the potential for antidepressant effects, multiple authors now rec-
ommend exercise of moderate-intensity and of at least 8 weeks
duration (Mead et al., 2008; Trivedi et al., 2011; Rimer et al.,
2012). PA regimens must be tailored according to the individual
patient’s functional status and other co-morbidities. Failing to do
so can lead to further morbidity and/or mortality. In patients with
social phobia-related symptoms, the approach to PA interventions
should be tailored appropriately.
NEUROIMMUNOLOGICAL EFFECTS OF PHYSICAL ACTIVITY
IN DEPRESSION
When considering the neuroimmunological effects of PA in
depression, it is important to first outline the current under-
standing on neuroimmunological mechanisms of the depression-
like disease states. Therefore, the following section will outline
these neuroimmunological mechanisms in detail; following, the
neuroimmunological effects of PA will be examined.
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NEUROIMMUNOLOGICAL CHANGES IN DEPRESSION
The neuroimmunological changes found in depression involve
humoral and cellular factors from both the innate and adaptive
immune systems (Eyre and Baune, 2012c; Littrell, 2012). Humoral
factors include PICs, AICs, C-reactive protein (CRP) as well as
other immunomodulatory factors like CX3CL1, CD200, and IGF-
1 (Eyre and Baune, 2012b). Cellular factors include resident glia
(e.g., astrocytes, microglia) and centrally migrating immune cells
involved in protective immunosurveillance (e.g., CD4+T cells and
macrophages; Eyre and Baune, 2012b).
Neuroinflammation and depression: a well recognized relationship
The neuroinflammatory state is well known to be associated with
the depressive phenotype (Dantzer et al., 2008; Dowlati et al.,
2010). For example, a recent meta-analysis found a significant cor-
relation between tumor necrosis factor (TNF-α), IL-6, and CRP
with depression in humans (Dowlati et al., 2010). Neuroinflamma-
tion is characterized by elevations in PICs and reductions in AICs
and can arise within the CNS itself,or peripheral inflammatory sig-
nals can be transferred into the CNS (Dantzer et al., 2008; see Quan
and Banks, 2007; for a review of peripheral-CNS pathways, includ-
ing: the neural route, circumventricular organs, BBB transport of
cytokines, and secretions from BBB cells). The neuroinflammatory
state is known to cause neurovegetative or sickness-like symptoms,
depression- and anxiety-like behaviors, as well as cognitive dys-
function and symptoms of Chronic Fatigue Syndrome (Dantzer
et al., 2008; McAfoose and Baune, 2009; Dowlati et al., 2010; Miller,
2010; Yirmiya and Goshen, 2011; Bansal et al., 2012), and the cau-
sation of these phenotypic states by PICs has been modeled in both
rodent and human models and extensively reviewed (Dantzer et al.,
2008; Miller, 2010).
Neuroinflammation-based models of depression have shown
PICs to impact on other major neurobiological systems involved
in depression. Neuroinflammation affects the neurotransmit-
ter systems by activation if the tryphophan degrading enzyme,
indoleamine 2,3 dioxygenase (IDO), altering metabolism of tryp-
tophan into neurotoxic metabolites (3-hydroxykyurenin, 3-HK
and quinolinic acid, QA) and depleting its availability for serotonin
(5-HT) synthesis (Miller, 2010; Dantzer et al., 2011; Moylan et al.,
2012). Inflammation also stimulates the reuptake of monoamines
from the synapse by increasing the activity and the density of
5-HT, noradrenaline, and dopamine transporters (Moron et al.,
2003; Nakajima et al., 2004; Zhu et al., 2006). Evidence suggests
these immune mechanisms adversely affected glutamatergic neu-
rotransmission causing GLU to rise to neurotoxic levels (McNally
et al., 2008; Hashimoto, 2009; Popoli et al., 2012). In the neuroin-
flammatory state PICs may disrupt the capacity of the glucocorti-
coid receptor to translocate to the nucleus where it normally acts
to suppress the activity of pro-inflammatory transcription factors
such as nuclear factor-kappa B (NF-κB) – this is termed glucocor-
ticoid resistance (Dantzer et al., 2008; Miller, 2010; Muller et al.,
2011). High levels of PICs impair processes of neuroplasticity in
the HC, such as neurogenesis, LTP, neurotrophin production (e.g.,
brain-derived neurotrophic factor, BDNF), and synaptic plasticity
(Miller, 2010; Eyre and Baune, 2012c). In the context of reduced
neuroplasticity, elevations in neurotoxic oxidative stress products
and markers of apoptosis are found in the HC (Moylan et al.,
2012). An in-depth assessment on the effects of inflammation on
these systems is outside the scope of this review and have been
outlined recently (see Dantzer et al., 2008, 2011; McAfoose and
Baune, 2009; Muller et al., 2011; Moylan et al., 2012).
Rationale for examining immune mechanisms in addition to
inflammation
Whilst the cytokine and neuroinflammatory models of depression
have been helpful in understanding the neurobiology behind the
depressive phenotype, there are a number of clinical and biological
reasons for investigating neuroimmune mechanisms in addition
to inflammation. These factors include:
• A recent meta-analysis by Hannestad et al. (2011) found results
arguing against the notion that resolution of a depressive episode
is associated with normalization of levels of circulating PICs.
This analysis of 22 studies (603 subjects) found – when all anti-
depressants were grouped – these medications reduced levels
if IL-1β with a marginal effect on IL-6 (using less stringent
fixed-effects models); there was no effect on TNF-α. However,
a sub-group analysis of selective serotonin regulate inhibitors
(SSRI) medication found a reduction in IL-6 and TNF-α. Other
antidepressants did not reduce PIC levels.
• Recent evidence has emerged to suggest no effect or even
an antagonistic effect for anti-inflammatory medications in
depression. A large-scale prospective cohort study of treatment-
resistant depression, the “sequenced treatment alternatives to
relieve depression” (STAR∗D), found an antagonistic effect
for anti-inflammatory compounds on ADs (Warner-Schmidt
et al., 2011). Patients reporting concomitant non-steroidal
anti-inflammatory drug (NSAID) or other analgesic treatment
showed a reduced therapeutic response to citalopram, hence, the
authors suggest concomitant use of NSAIDs may be an impor-
tant reason for high SSRI treatment resistance rates (Warner-
Schmidt et al., 2011). A recent re-analysis reached a similar
conclusion, with more modest effects persisting after adjustment
for potential confounding variables (Gallagher et al., 2012).
Another recently published study shows no difference between
infliximab, a TNF-α antagonist, and placebo in a recent 12-week
double-blind, placebo-controlled RCT for treatment-resistant
depression (Raison et al., 2012). There was a significant effect
for infliximab in individuals who had a high baseline hs-CRP
(>5 mg/L) and a significant effect for placebo-treated patients at
a baseline hs-CRP of <5-mg/L. Schwartz and Shechter hypoth-
esize anti-inflammatory drug compounds may block the pro-
duction of brain-derived cytokines and chemokines which pro-
mote the migration of neuroprotective immune cells involved
in protective immunosurveillance toward the CNS (Schwartz
and Shechter, 2010b; Warner-Schmidt et al., 2011). Importantly,
however, the use of NSAIDs may be most useful when used in the
correct stage of neuroinflammatory diseases, i.e., administered
early in the neuroinflammatory disease course when transmi-
gratory immune cells have not come into effect (Schwartz and
Shechter, 2010b).
• Evidence is emerging to suggest a neuroprotective and physi-
ological role for “PICs.” TNF-α and IL-6 have been shown to
play an integral roles in processes of memory and learning in
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both human and rodent studies, as well as having a physiolog-
ical role in HC neuroplasticity (Carlson et al., 1999; Eyre and
Baune, 2012c). The TNF-α gene (rs1800629) is correlated with
enhanced cognitive processing speed in a healthy human popu-
lation (Baune et al., 2008a). The IL-6 gene (rs1800795) has been
correlated with increased to HC volume in a healthy human pop-
ulation (Baune et al., 2012a). There are other studies outlining a
neuroprotective effect of PICs in the brain (see below).
• From a clinical disease course perspective, there are other mech-
anisms in depression – in addition to inflammation – which may
have a role in explaining the absence of correlation between the
increase in neuroinflammation in aging and rates of depression.
Since aging itself is related to higher levels of systemic inflamma-
tion and neuroinflammation (Hein and O’Banion, 2012), this
should lead to higher rates of depression in old age, however,
rates are highest in those aged 25–45 years, not in old age (Kessler
et al., 2005). Other neuroimmune factors which may explain this
scenario will be outlined below.
DYSFUNCTION OF NEUROPROTECTIVE IMMUNE FACTORS IN
DEPRESSION
When considering neuroimmunological factors in depression, his-
torically the focus has mainly been on high levels of PICs and their
detrimental effects on the brain. However, research is beginning to
suggest a significant role for neuroprotective neuroimmune factors
in depression and other neurobiological disorders (e.g., multi-
ple sclerosis and AD; Martino et al., 2011; Kokaia et al., 2012).
When considering these neuroprotective factors in depression,
their loss of function may exacerbate the depression-like behav-
iors (Schwartz and Shechter, 2010b). The following section will
outline evidence suggesting a possible beneficial role for a variety
of neuroimmune factors.
Neuroprotective and physiological effects of cytokines
There are a number of cytokines are found to have neuroprotective
and physiological effects.
Interleukin-6 has been found to have neuroprotective effects
via gp130 signaling and related pathways [i.e., Janus Kinase
(JAK)/Signal Transducer and Activator of Transcription (STAT),
Mitogen-activated Protein Kinase (MAPK)/cAMP Response
Element-binding (CREB), Ras-MAPK, Phosphatidylinositol 3-
kinases (PI3K); Baune et al., 2012a]. These mechanisms affect
the production of neurotrophic factors, cellular survival, and
apoptosis (Baune et al., 2012a). A recent imaging genetics study
investigated the association between the IL-6 gene and brain
morphology in a large cohort of healthy adult participants in
a whole-brain analysis approach (Baune et al., 2012a). Carri-
ers of the G-allele of the IL-6 genetic variant rs1800795 (-174
C/G) showed a significant association with larger HC volumes
on the right side in healthy subjects. This genotype effect was
remarkably specific to the HC, with no other structure surviv-
ing statistical threshold for the entire brain. The findings are
suggestive of a neuroprotective role of the IL-6 gene [rs1800795
(-174 C/G)] on HC morphology. Supporting a role of IL-6 in
neuroproliferation is an in vivo study showing that IL-6 knock-
out mice have reduced proliferating NSCs specifically in the HC,
hence underlining the importance of IL-6 in cell proliferation and
cell survival (Bowen et al., 2011). However, other similar studies
have shown no effect or a negative effect for IL-6 in neurogenesis
processes (Eyre and Baune, 2012c). The difference between the
pro- and anti-neurogenic effects of IL-6 may reflect differences
in amounts and conditions used experimentally (Eyre and Baune,
2012c).
Tumor necrosis factor-α is thought to exert its protective and
restorative effects primarily via TNFR2 (p75; primarily neuro-
protective and neuroregenerative pathway) and related signal-
ing pathways [i.e., IκB kinase (IKK)/Nuclear Factor κB (NF-kB),
Transforming Growth factor β-activated Kinase 1 (TAK-1), PI3K-
PKB-Akt, c-Jun N-terminal kinases (JNK), and IL-6), as opposed
to the TNFR1 (p55; primarily neurodegenerative; Eyre and Baune,
2012a; Santello and Volterra, 2012). Importantly, whether the out-
come of TNF-α signaling is protective or damaging may depend
upon duration of NF-κB activation (Santello and Volterra, 2012).
TNF-α has been found to exert beneficial effects in depression-
related processes, e.g., cognitive function and HC neurogenesis
(Eyre and Baune, 2012a; Santello and Volterra, 2012). During rel-
atively health aging processes, it has been shown that the TNF-α
gene (rs1800629) has protective effects on cognitive processing
speed (Baune et al., 2008a) and has been associated with cognitive
processes (e.g., response inhibition, error processing, attentional
processes, and mental rotation) in young health individuals (Eyre
and Baune, 2012a). In behavioral studies, TNF-α deficient mice
exhibit impaired HC-dependent memory function in the Morris
Water Maze suggesting that during early stages of brain develop-
ment basal levels of TNF is required for memory and learning
(Baune et al., 2008b).
Interleukin-4 has been found to have a beneficial role in
depression-like behaviors and a neuroprotective effect. The release
of IL-4 from CNS-specific autoreactive CD4+ T cells involved in
protective immunosurveillance – in response to increased neuro-
toxicity (Ron-Harel et al., 2011) – binds to IL-4 receptor on the
cytotoxic microglia (Kipnis et al., 2008) causing downregulation of
PIC production, induction of BDNF and IGF-1, and an elevation
in neurogenesis (Butovsky et al., 2005, 2006b; Lyons et al., 2009;
Martino et al., 2011). Microglia under quiescent conditions, after
exposure to IL-4 or low levels of IFN-γ (Butovsky et al., 2006b),
have been shown to support neurogenesis and NSC differentia-
tion and migration in vitro (Aarum et al., 2003; Butovsky et al.,
2006b; Walton et al., 2006). IL-4 is also shown to promote the
creation of neuroprotective M2-type microglial phenotype (God-
bout et al., 2012). A recent study found central IL-4 administration
increased microglial-specific M2a-type genes including Arginase,
IL-1Rα, and BDNF (Godbout et al., 2012). Microglia activated by
IL-4 remain committed to their protective phenotype (M2-type)
even when exposed to a threatening environment in the form
of LPS, and, exposure of microglia, pre-activated to a cytotoxic
phenotype, to IL-4 induces a phenotype switch toward neuropro-
tection (Butovsky et al., 2005; Schwartz et al., 2006). A study rodent
by Derecki et al. (2010) shows T cell-derived IL-4 to have benefi-
cial effects on the regulation of cognitive function in rodents via
meningeal myeloid cell phenotypes producing BDNF. IL-4 knock-
out mice show greater sickness behavior (measured by exploratory
behavior) than wildtype mice exposed to LPS (Lyons et al., 2009).
Interestingly, Kim et al. (2011) proposes T-bet deficient mice may
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have a neuroprotective effect by creating a predominance of Th2-
derived IL-4, which may in turn stimulate meningeal myeloid
cell BDNF production. T-bet is a Th1-specific T-box transcrip-
tion factor which regulates CD4+ Th1 development by inducing
endogenous Th1 cytokines, while simultaneously repressing Th2
development (Wong et al., 2008).
A role for IL-10 in neuroprotection and the prevention of
depression-like behavior has been suggested. Central adminis-
tration of IL-10 prevents the emergence of behavioral signs of
depression in an LPS model of sickness behavior (Bluthe et al.,
1999). IL-10 over-expression mice display less anxiety-like behav-
iors, while IL-10 knock-out rodents display greater anxiety and
depression-like behavior (forced-swim test) with these effects
more pronounced in females (Mesquita et al., 2008). In human
studies, IL-10 is found to be reduced in the depressed state (Him-
merich et al., 2010). Further papers examining the neuroprotective
effects of IL-10 can be found in Raison and Miller (2011).
Immunomodulatory factors
Insulin-like growth factor-1 is a major neurotrophic factor
involved in neuroplastic functions such as neurogenesis and is
critical in normal memory and LTP functions (Trejo et al., 2007).
Recent evidence suggests IGF-1 also has added immunomodula-
tory effects (Park et al., 2011a,b). In an LPS model of depression,
central administration of IGF-1 is shown to prevent LPS-induced
sickness- and depression-like behavior (Park et al., 2011a,b) in
association with an induction of BDNF and a reduction of TNF-α,
IL-1β, and iNOS in the pre-frontal cortex (PFC; Park et al., 2011b).
Given the levels of IGF-1 have been found to be low in rodent
models of depression (Mitschelen et al., 2011), the absence of this
anti-inflammatory factor may exacerbate the neuroinflammatory
and anti-neuroplastic state in depression.
CX3CL1 is a chemokine expressed by healthy neurons which
has its receptor, CX3CR1, in membrane bound form or as sol-
uble ligand (Rogers et al., 2011). It has an important role in
inhibiting the activation of microglia (Rogers et al., 2011). A
recent study with CX3CR1 knock-out mice and the LPS model
of sickness behavior found a deficiency in the action of CX3CL1
resulted in protracted microglial activation, as measured by IL-1β
and CD14 (Corona et al., 2010). These mice have extended LPS-
induced depression-like behavior in association with the activated
microglial phenotype described (Corona et al., 2010). In another
study with CX3CR1 knock-out mice, a lack of the CX3CR1 recep-
tor resulted in contextual fear conditioning (associative mem-
ory) and Morris Water Maze deficits (spatial memory), as well
as impairment in LTP (Rogers et al., 2011). Disruption of the
CX3CL1/CX3CR1-pathway in young rodents decreases both sur-
vival and proliferation of HC neural progenitor cells (Bachstetter
et al., 2011).
CD200 is a membrane glycoprotein which has been identi-
fied as an immune-suppressive molecule (Cox et al., 2012). It is
expressed in neurons and oligodendrocytes, but not on microglia
(Cox et al., 2012). The receptor for CD200, CD200R, is also a
membrane glycoprotein and is primarily restricted to cells of the
myeloid lineage, hence being found on microglia, but not neurons
or astrocytes (Cox et al., 2012). The interaction between CD200
and its receptor play a significant role in maintaining microglia
in a quiescent state, therefore, a decrease in CD200 expression
is associated with evidence of microglia activation (Cox et al.,
2012). A rodent study by Frank et al. (2007) shows an inescapable
shock model of stress over 24 h resulted in a downregulation of
HC CD200 in association with enhanced LPS-induced cytokine
production in HC microglia. This suggests stress can activate
microglia via downregulation of CD200, enhancing the PIC pro-
duction of microglia (Frank et al., 2007). A study by Cox et al.
(2012) found a CD200 fusion protein (CD200Fc), activator of
CD200R, attenuated age-related microglial immunoreactivity in
the HC (indicated by MHCII, CD40, and iNOS). CD200Fc also
attenuated LPS-induced microglial activation (indicated by ele-
vated MHCII, CD40, CD11b, and CD68) and LTP deficits (Cox
et al., 2012). Using CD200 knock-out mice and LPS-induced sick-
ness behavior, Costello et al. (2011) found the neuroinflammatory
changes resulting from CD200 deficiency have a negative impact
on LTP in the CA1 region of the dentate gyrus. Interestingly, a
study by Lyons et al. (2009) has shown IL-4 as a key inducer of
CD200 expression.
Dysfunction of protective immunosurveillance
Emerging data suggests a role for CNS-specific autoreactive
CD4+ T cells, blood-derived macrophages (in the form of M2
alternatively activated macrophages) in physiological, protective
immunosurveillance functions of the brain (Derecki et al., 2010,
2011; Martino et al., 2011; Ron-Harel et al., 2011). Evidence sug-
gests these cell types may have established a physiological con-
nection between the immune system and the brain, and have
assisted in explaining processes of HC-dependent neurogenesis
and cognitive dysfunction (Kipnis et al., 2004b; Butovsky et al.,
2006b, 2007; Ziv et al., 2006; Brynskikh et al., 2008; Derecki et al.,
2010, 2011), anxiety- and depression-like behavior (Cohen et al.,
2006; Lewitus et al., 2008; Cardon et al., 2010) due to an insuffi-
cient immune response (Derecki et al., 2010, 2011; Schwartz and
Shechter, 2010a,b; Ron-Harel et al., 2011). The role of these cells
in neuroprotection and higher neurocognitive functions has been
reviewed in detail elsewhere (Martino et al., 2011; Yirmiya and
Goshen, 2011); however, a brief summary will be given, below.
Immune cells involved in protective immunosurveillance can
populate meningeal areas of the choroid plexus and the cere-
brospinal fluid, hence gaining access to the healthy brain without
entering the parenchyma (Ransohoff et al., 2003; Derecki et al.,
2010, 2011; Schwartz and Shechter, 2010a). CNS-specific autore-
active CD4+T cells are suggested to react to three signals, (1) T-cell
receptor (TCR; Ron-Harel et al., 2011), (2) co-stimulatory signals
(CD28/CD80,86; Jenkins and Johnson, 1993), and (3) PICs and
reactive oxygen species (ROS; Curtsinger et al., 1999; Tse et al.,
2007; Ron-Harel et al., 2011). The T cells in question, activated
in response to increased neurotoxicity (Ron-Harel et al., 2011),
are thought to secrete increased levels of IL-4 (Ron-Harel et al.,
2011), where IL-4 penetrates the brain parenchyma and binds to
IL-4R on the cytotoxic microglia (Kipnis et al., 2008). Exposure of
cytotoxic microglia to IL-4 causes downregulation of PIC secre-
tion, induction of BDNF and IGF-1 secretion, and an elevation in
neurogenesis (Butovsky et al., 2005, 2006b; Martino et al., 2011).
All of these signals support the restoration of brain homeostasis
(Ron-Harel et al., 2011). Furthermore, the T cells boost infiltration
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of neuroprotective blood-borne monocytes upon need (Shechter
et al., 2009). A recent commentary by Ron-Harel et al. (2011)
suggests any destabilization in brain homeostasis that cannot be
locally contained by microglia and/or astrocytes will increase T cell
recruitment as well as subsequent IL-4 release and recruitment of
blood-derived macrophages.
According to the “protective immunosurveillance” model,
increased susceptibility to mental illness may result from a defi-
ciency in circulating T cells and the IL-4 they can produce, as the
IL-4 mediates processes which are able to counteract neuroinflam-
mation and restore brain homeostasis (Ron-Harel et al., 2011).
Indeed, the brains of immune-deficient mice show accumulation
of toxicity (i.e., increased glyoxalase-1, a compensatory mecha-
nism against free radical and carbonyl levels; Ron-Harel et al.,
2011).
According to the protective immunosurveillance model, activa-
tion of CNS-specific autoreactive CD4+T cells (mentioned above)
support the infiltration of neuroprotective, alternatively activated
M2 macrophages to the sub-arachnoid meningeal spaces and
choroid plexus, via IL-4 and IFN-γ secretion (Derecki et al., 2010,
2011; Ron-Harel et al., 2011). These infiltrating macrophages,
together with the microglia they regulate, remove dead cells and
cellular debris, buffer toxic compounds (such as GLU and ROS),
and produce growth factors (i.e., BDNF and IGF-1), while down-
regulating inflammation-associated compounds such as IL-1β,
TNF-α, iNOS, and COX-2 (Hauben et al., 2000; Butovsky et al.,
2005, 2006a,b, 2007; Shaked et al., 2005; Beers et al., 2008; Chiu
et al., 2008; Rolls et al., 2008; Shimizu et al., 2008; Koronyo-
Hamaoui et al., 2009; Shechter et al., 2009; Derecki et al., 2010,
2011; Prinz et al., 2011). These neurobiological functions are
thought to contribute to blood-derived macrophages support of
learning and memory (as determined via the Morris Water Maze
and Barnes Maze; Derecki et al., 2010, 2011). Importantly, intra-
venous injection of M2 cells into immune-deficient mice can
circumvent the need for CNS-specific autoreactive CD4+ T cells
(Derecki et al., 2011). For a review of the role of blood-derived
macrophages see recent papers (Derecki et al., 2010; Martino et al.,
2011; Yirmiya and Goshen, 2011).
The type of macrophage – classical (M1), alternatively acti-
vated (M2), and deactivated types – determines the role in sickness
behavior (for thorough review see Moon et al., 2011). Classical
macrophages produce PICs and, hence, induce sickness behaviors
(Dantzer et al., 2008; Moon et al., 2011). M2 macrophages which
reduce PIC production, as outlined above, are associated with a
reduction in sickness behavior (Derecki et al., 2010, 2011; Sherry
et al., 2010). Deactivated macrophages which inhibit PIC produc-
tion via IL-10 secretion are also thought to have beneficial effects
of sickness behaviors, however, this finding has not been replicated
(Moon et al., 2011).
It is important to mention a recent critique of the protective
immunosurveillance concept recently produced by Rook et al.
(2011). One important issue raised is that the phenotype of the
neuroprotective, CNS-specific autoreactive CD4+T cells is poorly
understood (Rook et al., 2011). The authors suggest immune cells
involved with the function of protective autoimmunity is likely
from a regulatory cell – not always CD25+ – given the involve-
ment of IL-4 and IL-10. Suggestions for potential cell types include
Th3, Tr1, Th2, IL-10+TH1, CD8+ reg cells, regulatory Foxp3+
NKT, IL-10+CD56brightNK, or various other IL-10-secreting cell
types (Fujio et al., 2010; Rook et al., 2011). Another important
consideration raised is the effect of T cell produced IL-4 on T reg
differentiation. T cell differentiation into the T reg cell type can be
enhanced or opposed by IL-4 depending on the context (Chapo-
val et al., 2010; Rook et al., 2011). Further, one study shows IL-4
increased certain chemokines (CCL1, CCL17, and CCL22) in an
experimental autoimmune encephalitis (EAE) model capable of
recruiting T regs (Butti et al., 2008). The above mentioned issues
are relevant to the neuroimmune model of depression considering
the dynamic relationship between T regs and effector T cells.
Glial cells
The role of the immunocompetent glia, astrocytes, and microglia,
in depression is complex and poorly understood (Beumer et al.,
2012); importantly, however, there is a developing literature sup-
porting a neuroprotective effect of these cells under certain con-
ditions (Schwarz and Bilbo, 2011, 2012; Ekdahl, 2012). The follow
section will summarize most recent evidence available in this field.
Microglia
The function of microglia is dynamic even in the resting state
whereby they continually survey their microenvironments by
extending and contracting processes into nearly synapses (Bilbo
et al., 2012). Microglia are the resident macrophages of the CNS
and are recognized as the primary component of the neuroim-
mune system (Ekdahl, 2012). Once activated – by chronic stress
conditions, or immune challenge with LPS or PICs – microglia
are capable of producing PICs and neurotoxic mediators such as
nitric oxide, PGE2, and superoxide anions (Liu et al., 2011; Bilbo
et al., 2012; Ekdahl, 2012). A recent study by Walker and col-
leagues has shown a role for microglia in mediating the effects
of stress on PFC neuronal function and PFC-regulated behavior
(Hinwood et al., 2012). This study found restraint stress conditions
caused a decline in working memory performance associated with
increased microglial activity (measured by a 25% increase in Iba-1
labeling, ∆FosB, and a hyper-ramified state) in the medial PFC
and no association was found with increased antigen presentation
(MHCII) or apoptosis (caspase-3; Walker et al., 2011).
Given the pre-existing association with the inflammatory
hypothesis of depression much research centers on reducing the
PIC production of microglia (Liu et al., 2011). Recent evidence
suggests a neuroprotective function of microglia under certain
circumstances (Yirmiya and Goshen, 2011; Ekdahl, 2012). For
example, microglia under quiescent conditions, after exposure
to IL-4 or low levels of IFN-γ (Butovsky et al., 2006b), have
been shown to support neurogenesis and NSC differentiation and
migration in vitro (Aarum et al., 2003; Butovsky et al., 2006b; Wal-
ton et al., 2006). Microglia activated by IL-4 remain committed
to their protective phenotype even when exposed to a threatening
environment in the form of LPS, and, exposure of microglia pre-
activated to a cytotoxic phenotype to IL-4 induces a phenotype
switch toward neuroprotection (Butovsky et al., 2005; Schwartz
et al., 2006). Exposure of rats to environmental enrichment (EE)
increases neurogenesis alongside increased HC microglia prolifer-
ation (microglia assumed a neuroprotective phenotype expressing
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MHC II and IGF-1; Ziv et al., 2006). As mentioned previously,
the pro-neurogenic effects of microglia may be related to their
interactions with CNS-specific autoreactive CD4+ T cells, this
was further confirmed by a study showing transgenic mice with
an excess of these T cells – and associated increases in neuro-
genesis – showed attenuated neurogenesis by chronic treatment
with the microglial inhibitor, minocycline (Ziv et al., 2006). Fur-
thermore, a rodent model of amyotrophic lateral sclerosis (ALS)
illustrates the interaction between T cells and microglia whereby
Th1 cytokines promote M1 microglia and Th2 or Treg cytokines
promote M2 microglia (Chiu et al., 2008). Microglia were also
shown to support neurogenesis in adrenalectomized rodents via
TGF-β (Battista et al., 2006; Mathieu et al., 2010). Opposing the
above neuroprotective findings is a rodent study demonstrating
that PA-induced neurogenesis was not associated with microglial
proliferation or activation, and no indication of T-cell-microglial
interactions (i.e., no MHC II expression or T cells in the HC; Olah
et al., 2009).
In summary, microglial function is closely intertwined with the
immune system and neurogenesis (Ekdahl, 2012), with the cross-
talk between these systems requiring further investigation. For
instance, a recent review by Ekdahl (2012) suggests microglial acti-
vation patterns may by region-specific. Moreover, there appears to
be a primarily beneficial interaction between microglia and new
neurons in the intact brain, however, the cross-talk is complex
and probably double-edged in pathological conditions, especially
following long-term microglial activation (Ekdahl, 2012).
Astrocytes
Astrocytes are physically and functionally appositioned with most
synapses, known as the “tripartite synapse” (Araque et al., 1999).
They possess immune-like properties whereby they have an abil-
ity to respond to inflammatory cytokines (particularly IL-1β), to
secrete PICs (i.e., TNF-α and IL-6) and to phagocytose cellular
processes and debris (Yirmiya and Goshen, 2011). These cells play
an important role in neural and synaptic functioning. For exam-
ple, a rodent study by Bracchi-Ricard et al. (2008) shows female
mice where the transcription factor NF-κB was inhibited specifi-
cally in astrocytes displayed deficits in learning, memory, and LTP.
These cells were also found to mediate homeostatic synaptic scal-
ing following prolonged inhibition of neuronal activity via TNF-α
secretion, a known synaptic strength enhancer (Stellwagen and
Malenka, 2006; Kaneko et al., 2008). The role of astrocytic IL-1
signaling in memory functioning and LTP was recently demon-
strated by Ben Menachem-Zidon et al. (2011). In this study neural
precursor cells (NPCs) derived from either WT or IL-1rKO neona-
tal mice were labeled with BrdU and transplanted into the HC of
either IL-1rKO or WT adult host mice. Transplanted NPCs showed
long-term survival and differentiated into astrocytes (expressing
GFAP and S100β), but did not differentiate into neurons. Sev-
eral weeks post-transplantation, IL-1rKO mice transplanted with
IL-1rKO cells, or sham operated, displayed severe memory distur-
bances and a marked impairment in LTP. However, IL-1rKO mice
transplanted with WT NPCs (expressing IL-1R) displayed com-
plete rescue of the impaired memory functioning, as well as partial
restoration of LTP. IL-4 is also found to be important in astro-
cyte functioning with the secretion of BDNF by in vitro astrocytes
being markedly enhanced by this cytokine (Martino et al., 2011).
Furthermore – and in fitting with the abovementioned model of
protective immunosurveillance by Schwartz et al. – astrocytes also
acquire a neuroprotective phenotype following their co-culture
with T cells (Garg et al., 2008).
There is a paucity of evidence correlating the role of the above-
mentioned glial cells in models and tests of depression-like behav-
ior. This is an important area for future research as these cells
appear to be involved in depression-related pathophysiological
processes.
Additional cellular immune factors
The role of T regs in depression is uncertain, and may be both posi-
tive and negative in depression pathophysiology depending on the
surrounding environment (Cohen et al., 2006; Himmerich et al.,
2010). In relation to the positive effects of T regs, some authors
propose these cells may function to inhibit inappropriate or exces-
sive immune responses, i.e., PIC production (Dantzer et al., 2008;
Miller, 2010). Some human studies have found reduced IL-10 and
TGF-β have been found in depressed patients, and are thought
to be consistent with reduced T reg expression and/or function
(Myint et al., 2005; Sutcigil et al., 2007; Dhabhar et al., 2009; Musil
et al., 2011). One study found decreased T regs, alongside intra-
cellular Foxp3, in association with IL-10 and TGF-β in depressed
patients vs. controls (Li et al., 2010). A second study found 6 weeks
of AD treatment led to increased T reg (CD4+CD25hi) percent-
age in association with decreased IL-1β (Himmerich et al., 2010).
A recent rodent study shows T reg cell depleted mice undergo-
ing chronic immobilization stress displayed markedly increased
anxiety in the Elevated Plus Maze and increased depression-like
behavior in the Forced-Swim Test (Kim et al., 2012). These finds
were found in correlation with elevated serum cytokines (i.e., IL-
6, TNF-α, IL-2, IFN-γ, and IL-4) and reduced levels of HC 5-HT.
In addition, a rodent model of cholestatic liver disease due to
bile duct ligation found T regs suppress sickness-like behavior
alongside inhibiting monocyte and hepatic IL-6 production, and
subsequent signaling via circulating IL-6 acting (via p-STAT3 at
the level of the cerebral endothelium; Nguyen et al., 2012). How-
ever, T regs have also been found to inhibit the beneficial effects
of CNS-specific autoreactive CD4+ T cells on mitigating stress-
induced anxiety-like behaviors in rodents (Cohen et al., 2006).
This suggests T regs may inhibit the neuroprotective functions of
these autoreactive T cells, a counterproductive effect. Interestingly,
other studies with an optic nerve injury model have shown both
Treg-free CD4+ T cells and T regs, respectively, can exhibit neuro-
protective functions via preventing neuronal cell loss (Kipnis et al.,
2004a). T regs exhibit significant plasticity and can lose regulatory
activity, expressing effector cell function under certain circum-
stances (Zhou et al., 2009). Therefore, the balance of these two cells
types may play a role in neuroprotective functions. Interestingly,
T regs constitutively express CD25, a high affinity IL-2 receptor.
The expression of CD25 is thought to be one of the ways by which
T regs suppress proliferation of T effector cells, that is, by acting
as a sink for IL-2 which is needed for T effector cell proliferation
(Walsh and Kipnis, 2011). Interestingly, IL-2 is known to increase
the suppressive abilities of T regs (Kohm et al., 2006), hence, the
reduction of IL-2 which is seen in some studies of depression may
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reduce the anti-inflammatory effects of T regs (Anisman et al.,
1999; Blume et al., 2011). A recent review paper summarizes lit-
erature suggesting T reg phenotypes are flexible depending on
background chemokine and cytokine levels (Rook et al., 2011).
Flexibility of phenotype means these cells can change from anti-
to pro-inflammatory functions (Rook et al., 2011); indeed, authors
remark that T-cell phenotype may change from the start to the end
of studies (Rook et al., 2011). Furthermore, gut microbiota may
affect the immunosuppressive function of T regs as well as their
effects on higher neurocognitive behaviors of the brain (Rook et al.,
2011). Clearly, the effect of T regs in depression requires further
research.
Other T-cell subtypes in depression – Th1, Th2 cells, and T-bet
The balance of Th1 vs. Th2 cytokines in depression is currently
debated by prominent authors in the field (Capuron and Miller,
2011; Rook et al., 2011). The majority of evidence suggests a
net Th1 production as a key feature of immune dysfunction in
depression, however, some studies suggest increased Th2 produc-
tion (Myint et al., 2005; Capuron and Miller, 2011; Rook et al.,
2011; Leonard and Maes, 2012). Th1 cells can produce IFN-γ, IL-
2, and TNF-α; Th2 cells can produce IL-4, IL-6, and IL-10. Recent
evidence suggests T-bet is associated with depression-like behav-
iors (Wong et al., 2008; Kim et al., 2011). T-bet deficient mice,
Th1/IFN-γ depleted, are shown to be resistant to stress-induced
depression-like behavior and stress-induced neuroinflammation
(i.e., IL-6 and TNF-α; Kim et al., 2011). A clinical study by Wong
et al. (2008) in a sample of Mexican Americans with major depres-
sion, shows evidence that single nucleotide polymorphisms (SNPs)
in the T-bet (Tbx21) gene, which is critical for helper T (Th) 1-cell
function, are associated with susceptibility to major depression.
Moreover, the same study showed T-cell involvement in AD treat-
ment response of genes associated with T-cell development (T-cell
antigen receptor-ε subunit of T3, CD3E; Wong et al., 2008).
BALANCING BENEFICIAL AND DETRIMENTAL EFFECTS OF THE
NEUROIMMUNE SYSTEM IN DEPRESSION
In the sections above we have outlined both the beneficial and
detrimental effects of the neuroimmune system in depression.
From this information, we suggest that depression-related patho-
physiology and depression-like behaviors may be dictated by the
balance between the beneficial and detrimental effects of neuroim-
mune factors. See Figure 1 for a graphical representation of this
balance. It is possible that when the balance is skewed toward the
detrimental effects of the neuroimmune system, this leads to the
development of depression-like behaviors, may prolong depressive
episodes and lead to more severe symptomatology and behaviors.
Alternatively, if the balance becomes skewed toward the beneficial
effects of the neuroimmune system, this would reduce symptoma-
tology and behavior and may drive the end of depressive episodes
and prolong relapse remission.
NEUROBIOLOGICAL EFFECTS OF PHYSICAL ACTIVITY IN DEPRESSION
The neurobiological effects of PA in depression include effects on
neurotransmitter, neuroendocrine systems, effects on neuroplas-
ticity, and effects on neuroimmunological factors. The following
section will outline the effects of PA on these systems, below, with
a focus on neuroimmunological factors.
Neurobiological effects
Physical activity has been shown to upregulate monoamine neu-
rotransmitters in the brain (e.g., 5-HT, dopamine, and noradren-
aline) as well as endorphins (Knochel et al., 2012; Lautenschlager
et al., 2012; Sarris et al., 2012). Reductions in glucocorticoid
stress hormones are also found alter PA interventions whereby
PA appears to re-regulate the HPA axis (Eyre and Baune, 2012c).
Oxidative stress is reduced in the hippocampus in pre-clinical
populations (Marosi et al., 2012).
Hippocampal neuroplasticity (e.g., neurogenesis, HC volume,
and neurotrophin production) is increased with PA interventions
in both clinical and pre-clinical populations (Erickson et al., 2012;
Knochel et al., 2012; Lautenschlager et al., 2012). Pereira et al.
(2007) reported that aerobic exercise resulted in increased HC
blood volume which correlated with improved aerobic capac-
ity and neurogenesis in the dentate gyrus. A recent RCT by
Erickson et al. (2011) found that an aerobic exercise program
in older adults, for 3 days a week over 1 year, increased HC vol-
ume by 2%. This was associated with increased serum BDNF
and improvements in spatial memory. Further work is required
to investigate the effects of PA on neuroplasticity in the PFC and
amygdala.
Neuroimmunological effects in clinical populations
A recent study by Rethorst et al. (2012) aimed to determine the
extent to which inflammatory markers can be used to predict
treatment response to exercise treatment, and if this effect was
dependent upon the dose of exercise. This prospective study used
participants who were incomplete responders to an SSRI and ran-
domized them to two doses of aerobic exercise for 12 weeks [4 or
16 kilocalories per kilogram of body weight per week (KKW))]
16 KKW was designed to meet or exceed current PA guidelines
for public health from professional associations. The study found
participants with a high baseline TNF-α (>5.493 pg/ml) had a
greater reduction in depressive symptoms (measured by IDS-C)
than those with a low TNF-α level. Interestingly, this finding may
suggest TNF-α as a moderator between SSRI and exercise treat-
ment, and TNF-α levels could be used to recommend exercise
rather than medication as part of a personalized treatment algo-
rithm (Rethorst et al., 2012). This is given Eller et al. (2008) found
high baseline TNF-α associated with non-response to an SSRI, and
the Hannestad et al. (2011) meta-analysis also supports this associ-
ation. There was a significant correlation between change in IL-1β
and depression symptoms for the 16 KKW group, but not the 4
KKW group. The meta-analysis by Hannestad et al. (2011) also
found a reduction in IL-1β correlated with better outcomes with
SSRIs. Interestingly there was no change in cytokines levels fol-
lowing either exercise dosage. The authors suggest this may have
occurred due to pre-treatment with SSRIs – a well known anti-
inflammatory agent (Hannestad et al., 2011) – which obscured
the ability to detect changes in cytokine levels. Indeed, many past
studies have shown exercise to have a robust anti-inflammatory
effect in both human and rodent studies (Rethorst et al., 2011;
Eyre and Baune, 2012a).
Another recent study by Irwin and Olmstead (2012) utilized a
9-week TCC program in a healthy older adult population to inves-
tigate the effect of exercise on depression symptoms. This study
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FIGURE 1 | Depression-like behavior: balancing the beneficial and
detrimental effects of the neuroimmune system. (A) This section shows
the balance of the detrimental (red) and beneficial (green) effects of
neuroimmune factors in the depressed state (i.e., detrimental factors out way
beneficial factors). NB: depression-like behavior includes sickness-like
behavior, anhedonia, anxiety-, and cognition-like behaviors. (B) This section
shows a number of potential outcomes for the balance between the
abovementioned neuroimmune factors. (i) Shows a net detrimental effect
which would lead to depression-like behaviors; clinically this could mean a
depressive episode and could also increase relapse rates. (ii) Shows an
equilibrium position which may suggest a stable/steady state in behavior;
clinically this could mean a euthymic state. (iii) Shows a net beneficial effect
which may attenuate depression-like behavior; clinically this could mean
reduction or resolution of depressive symptoms and reduced relapse rates.
found TCC reduced depressive symptoms (BDI) in correlation
with a reduction in IL-6 levels. TCC, however, had no effect on
cellular markers of inflammation (i.e., sIL-1ra, sIL-6, sICAM, and
IL-18). The authors suggest PA treatments may modulate IL-6
via decreasing sympathetic outflow. Aging and stress are associ-
ated with increases in circulating catecholamine levels, which are
known to increase IL-6.
A study by Kohut et al. (2006) found aerobic exercise reduced
pro-inflammatory factors (i.e., CRP, IL-5, TNF-α, and IL-18) more
than a combination of flexibility and strength exercise over a
10-month period. These exercise types both reduced depressive
symptoms in the Geriatric Depression Scale (GDS).
The robust lipolytic effects of PA are suggested to play a role
in the antidepressant effects of PA in depression, via reducing the
systemic pro-inflammatory state seen in obesity (Gleeson et al.,
2011). A high visceral fat mass has been shown to cause a chronic
inflammatory state, and this chronic inflammatory state may link
depression and obesity (Stuart and Baune, 2012). Gleeson et al.
(2011) also suggests physical inactivity is a risk factor for the
accumulation of visceral fat which may predispose individuals to
chronic illness like depression and heart disease via systemic PIC
production by visceral fat mass.
See Tables 1 and 2 for clinical studies examining the effects
of exercise on neuroimmunological factors with and without
depressive symptom correlations, respectively.
Neuroimmunological effects in pre-clinical populations
As seen in Tables 3 and 4, there are a large number of studies inves-
tigating the neuroimmunological effects of PA. Studies have been
variously conducted with and without behavioral correlates. The
following section will summarize the salient studies in this field.
A recent study found a voluntary exercise regimen to be associ-
ated with increased HC MIF, as well as Bdnf and Tph2 (tryphophan
hydroxylase, involved in the synthesis of 5-HT) gene expression
(Moon et al., 2012). These changes occurred in the context of
reduced depression-like behavior (FST), and the effect of PA on
these factors was mediated by the CD74-GTPase (MIF recep-
tor) and RhoA-ERK1/2 pathway. MIF is a PIC expressed in the
CNS whose deletion is associated with increased anxiety- and
depression-like behaviors, as well as of impaired HC-dependent
memory and HC neurogenesis (Conboy et al., 2011). Taken
together, this information suggests a role of MIF in mediating the
antidepressant action of exercise, probably by enhancing 5-HT
neurotransmission and neurogenesis.
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Other studies found investigating the effects of PA
on neuroimmune-related factors suggest PA increases anti-
inflammatory or immunomodulatory factors, e.g., IL-10, IGF-1,
and CX3CL1. Sigwalt et al. (2011) shows that in a rat model of
depression induced by repeated dexamethasone administration,
swimming exercise reduces depression-like behavior in correlation
with increased HC IL-10, BDNF, and DNA oxidation. Duman et al.
(2009) and Kohman et al. (2012) show voluntary wheel running
associated with increased IGF-1, a factor recently shown to have
anti-inflammatory effects.
Physical activity has been found to have beneficial effects on
immunocompetent glial cells. A study by Latimer et al. (2011) has
shown PA to revise age-related astrocyte hypertrophic/reactivity
and myelin dysregulation – changes associated with neuroin-
flammation, cognitive decline, and reduced vascular function.
Kohman et al. (2012) recently published a study showing PA
attenuates aging associated increases in the proportion of new
microglia within the HC (Iba-1 labeled). Furthermore, they show
PA increases the pro-neurogenic phenotype of microglia (i.e.,
IGF-1-releasing microglia) which may contribute to increased HC
neurogenesis. Given the robust anti-inflammatory effect of PA, the
authors suggest PA may reduce PIC protein production leading
to impaired microglial proliferation. A recent study by Barrien-
tos et al. (2011) shows access to a running wheel reduced PIC
expression from cultured microglia of aged rats. A recent study by
Vukovic et al. (2012) suggests PA enhances the immunomodula-
tory factor CX3CL1 in the HC, with this associated with enhanced
microglia-dependent neural precursor activity, as per the ex vivo
neurosphere assay.
A study by Funk et al. (2011) demonstrates that PA can offer
significant protection to the HC in a chemical-induced injury
model [via trimethyltin (TMT)] that involves TNF receptor sig-
naling. PA attenuated TMT-induced changes such as loss of DG
neurons and microglial activation. Furthermore, PA was accompa-
nied by a significant elevation in IL-6 and IL-1ra mRNA levels and
repressed elevations in PICs and chemokines (CCL2 and CCL3).
Interestingly, the investigators identified a functional role for IL-6
in neuroprotection given mice deficient in IL-6 (IL-6 knock-out)
were not responsive to the neuroprotective effects of PA on the
HC. The effects of PA and TMT on IL-6 downstream signal events
differed at the level of STAT3 activation. The beneficial effects of
acute spikes in IL-6 with PA is clearly a significant factor in the
anti-inflammatory effect of PA. In a human study by Starkie et al.
(2003), 3 h of cycling blunted the endotoxin-induced increase in
circulating TNF-α levels, and this effect was mimicked by an IL-6
infusion. Further, this regulatory role of IL-6 on TNF-α levels was
demonstrated in anti-IL-6 treated mice and IL-6 knock-out mice
(Mizuhara et al., 1994; Matthys et al., 1995). Whilst acute eleva-
tions in IL-6 are found throughout the body (Funk et al., 2011), a
recent study shows a selective increase in IL-6 localized to the HC
(Rasmussen et al., 2011).
Neuroimmune cells may also have a role in the beneficial effects
of PA. A study by Ziv et al. (2006) found PA, a component of the EE
protocol, was associated with enhanced HC neurogenesis along-
side a neuroprotective microglia phenotype and in the presence
of a T-cell population. The role of CNS-specific T cells in the
neuroprotective effects of PA is suggested given severe combined
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immunodeficiency (SCID) mice exposed to EE did not show an
increase in neurogenesis.
MODEL OF NEUROIMMUNOLOGICAL EFFECTS OF PA IN
DEPRESSION
Emerging evidence suggests the neuroimmune system is critical
in both the development of depression-related pathophysiology
and in the treatment of depression. From the evidence available
in this field, PA has a multitude of beneficial neuroimmune effects
which may lead to the improvement of depression-related neu-
robiological processes, hence leading to reduced depression-like
behaviors.
From a neuroimmune perspective, evidence suggests PA does
enhance the beneficial and reduce the detrimental effects of the
neuroimmune system. Figure 2 outlines these effects. PA appears
to increase the following factors: IL-10, IL-6 (acutely), MIF, CNS-
specific autoreactive CD4+ T cells, M2 microglia, quiescent astro-
cytes, CX3CL1, and IGF-1. On the other hand, PA appears to
reduce detrimental neuroimmune factors such as: Th1/Th2 bal-
ance, PICs, CRP, M1 microglia, and reactive astrocytes. The effect
of other factors is unknown, such as: T regs, CD200, chemokines,
miRNA, M2-type blood-derived macrophages, and TNF-α (via
R2). The beneficial effects of PA are likely to occur centrally and
peripherally (e.g., in visceral fat reduction).
Based on the strong relationship between the neuroimmune
system and other neurobiological systems (i.e., neuroplasticity,
neuroendocrine function, and neurotransmission), we believe
PA may exert beneficial behavioral effects via these neurobio-
logical systems. PA’s neuroimmune effects are likely involved in
enhanced neuroplasticity, reduced oxidative stress, increases in 5-
HT, dopamine, and noradrenaline, and enhanced glucocorticoid
sensitivity.
The neurobiological effects of PA – mediated largely via
the neuroimmune system – are likely involved with reduced
depression-like behaviors in rodents (i.e., sickness-like behav-
ior, anhedonia, anxiety-, and cognition-like behaviors) and posi-
tive clinical effects (i.e., reduced depressive symptoms, enhanced
cognitive function, relapse reduction, and early intervention).
DISCUSSION
Physical activity is increasingly investigated as a preventative, early
intervention, and treatment option in depression. The interest in
investigation of PA may have arisen for a number of reasons: the
burden of depression is rising so novel therapeutic and preven-
tative options are required (WHO, 2008; Berk and Jacka, 2012;
Cuijpers et al., 2012; Southwick and Charney, 2012). Rates of
physical inactivity are high and rising in modern society (Lee
et al., 2012) with early evidence suggesting a link to the devel-
opment of depression (Pasco et al., 2011a,b). Pharmacotherapy
in depression is hampered by relatively high rates of resistance
(Rush et al., 2006a,b) and considerable side-effects. Evidence is
emerging to suggest co-morbid links between obesity, diabetes,
FIGURE 2 | Physical activity in depression: antidepressant via
enhancing the beneficial effects of the neuroimmune system. This
figure illustrates the effects of PA on the brain as per the balance
between beneficial and detrimental effects of neuroimmune factors.
PA appears to enhance the beneficial effects of the neuroimmune
system and reduce the detrimental effects. From a behavioral
perspective, this may lead to reduced depression-like behaviors. From a
clinical perspective, this may lead to reduced depressive symptoms,
depressive episode resolution, and reduced relapse rates (disease
prevention).
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heart disease, and depression (Baune and Thome, 2011; Stuart
and Baune, 2012), and PA is a therapeutic option with benefi-
cial cardio-metabolic effects (Gleeson et al., 2011; Baune et al.,
2012c; Hamer et al., 2012; Knochel et al., 2012; Stuart and Baune,
2012).
Based on the abovementioned factors, research has been
reviewed to better understand the clinical efficacy of different
types of PA, to understand the mechanism of action of PA and
to investigate for suitable biomarkers to measure the treatment
effect of PA in depression. Further, a model has been suggested in
order to assist in understanding the neuroimmune effects of PA in
depression.
An important consideration in the field of exercise immunology
includes understanding the mechanisms of treatment response in
depression vs. other psychiatric disorders. At present the authors
feel there is no enough data to address this issue systematically,
with research evidence. Whilst it would appear that the effects of
PA on the immune system in various disorders – in both clinical
and pre-clinical studies – is quite similar, i.e., PICs are reduced
(particularly in anxiety disorders and depression; Gleeson et al.,
2011; Eyre and Baune, 2012a), this considers only a narrow range
of neuroimmune factors. The authors speculate that the thera-
peutic difference in PA may occur due to subtle variations in
the neuroimmune and neurobiological effect, dependent upon
the CNS environment with each pathophysiological state. Stud-
ies investigating the effects of a standardized exposure to PA, in
various psychiatric disorders in parallel, may assist in unraveling
this complex issue.
When considering the balance between the beneficial and detri-
mental effects of immune system and the effect of PA tipping this
balance toward beneficial effects, it is important to consider: Is it
possible to restore the balance of the immune system and still suf-
fer from a low mood? This is an interesting question and open
to debate. It would seem that the majority of evidence suggests
that as inflammation increases, mood worsens, and as inflamma-
tion reduces, mood appears to return to normal. For example,
this is shown in meta-analysis by Dowlati et al. (2010) and a
review by Maes (2011) whereby depressive symptoms are asso-
ciated with elevations in PIC levels. Another meta-analysis shows
inflammation reduces with the use of SSRIs in the treatment of
depression (Hannestad et al., 2011). However, there are other ther-
apies such as SNRIs which appear to improve mood, yet have no
effect on levels of inflammation (Hannestad et al., 2011). There-
fore, more work is required to understand the effect of various
therapies (pharmacological and non-pharmacological) on a wider
variety of immune-related factors such as cytokines (anti- and
pro-inflammatory), anti-inflammatory factors like IGF-1, CD200,
CX3CL1, MIF, neuroprotective systemic immune cells, etc. Inter-
estingly, Walker (2012) suggests the concentration of antidepres-
sant drug molecules in the CNS also alters the immunomodulatory
effects.
FUTURE DIRECTIONS
From current evidence, it is not possible to ascertain the type of PA
which is most efficacious in the treatment of depression. Although,
most evidence surrounds aerobic exercise. We suggest the need for
head-to-head clinical trials comparing different types and inten-
sities of PA to assist in making this issue clearer. Moreover, when
considering the effects of distinct types of PA on neuroimmune
factors, we also suggest the need for more head-to-head clinical
trials (Baune and Eyre, 2012).
The most recent study examining the effects of PA on depressive
symptoms was conducted by Rethorst et al. This study suggests that
a high baseline TNF-α level was associated with a greater reduction
in depressive symptomatology as opposed a high baseline TNF-α
level being a negative factor for SSRI efficacy (Hannestad et al.,
2011; Rethorst et al., 2012). The authors suggest TNF-α levels may
be a moderator between SSRI and exercise treatment, and may
have a role in personalized treatment algorithms. Whilst this is a
promising suggestion, further research is needed to replicate these
findings.
Our understanding of the neuroimmune effects of PA in
depression will continue to develop as the understanding of the
neuroimmune effects of PA develop. It is important to consider
the use of multi-biomarker methods within this area in order to
better understand potential biomarkers. For example, the use of
neuroimaging, serum protein and genetic markers, and behav-
ioral analysis. This type of methodology is increasingly employed
in biological psychiatry (Baune et al., 2010, 2012a,b).
There are a number of neuroimmune-related factors which are
yet to be considered in the effect of PA in depression. These factors
include micro ribonucleic acid (miRNA), neuroimmune-related
Positron Emission Tomography (PET) ligands, the neuroprotec-
tive effects of neuroimmune factors, and immune cells. Evidence is
emerging to suggest a role for miRNAs, factors involved in regulat-
ing gene expression at the post-translational level, in modulating
the effects of the immune system (Ponomarev et al., 2012). For
example, various miRNAs such as miR-155 and miR-124 may have
a role in polarizing microglia toward pro- or anti-inflammatory
phenotypes, respectively (Ponomarev et al., 2012). The PET lig-
and, Translocator Protein (TPSO) ligand [(11)C]PBR28, a marker
of microglial activation, was recently found to be elevated by LPS-
induced systemic inflammation in non-human primates (Hannes-
tad et al., 2012). This ligand has the potential to be utilized as a
biomarker to investigate if activation of microglia may be a mech-
anism through which systemic inflammatory processes influence
the disease course of depression. The biology of centrally migrating
immune cells and CNS immune cells in depression is complex and
far from understood. Regarding the debated issue of blood-derived
macrophages can enter the brain parenchyma: research and devel-
opment into novel methods for permanent differential labeling
of circulating monocytes, as contrasted with resident microglia,
is underway (Prinz et al., 2011). Studies are required to better
understand the role of protective immunosurveillance in clinical
and rodent models of depression.
CONCLUSION
The investigation of the neuroimmune effects of PA on depression
and depression-like behavior is a rapidly developing and impor-
tant field. This paper summarizes the most recent findings in the
area and proposes a model whereby PA enhances the beneficial
effects of the neuroimmune system and reduces the detrimental
effects of the neuroimmune system.
www.frontiersin.org February 2013 | Volume 4 | Article 3 | 21
Eyre et al. Neuroimmune effects of physical activity
REFERENCES
Aarum, J., Sandberg, K., Haeberlein, S.
L., and Persson, M. A. (2003). Migra-
tion and differentiation of neural
precursor cells can be directed by
microglia. Proc. Natl. Acad. Sci.
U.S.A. 100, 15983–15988.
Anisman, H., Ravindran, A. V., Griffiths,
J., and Merali, Z. (1999). Endocrine
and cytokine correlates of major
depression and dysthymia with typ-
ical or atypical features. Mol. Psychi-
atry 4, 182–188.
Araque, A., Parpura, V., Sanzgiri, R. P.,
and Haydon, P. G. (1999). Tripar-
tite synapses: glia, the unacknowl-
edged partner. Trends Neurosci. 22,
208–215.
Asmundson, G. J. G., Fetzner, M.
G., DeBoer, L. B., Powers, M. B.,
Otto, M. W., and Smits, J. A. J.
(2013). Let’s get physical: a con-
temporary review of the anxiolytic
effects of exercise for anxiety and
its disorders. Depress. Anxiety. doi:
10.1002/da.22043. [Epub ahead of
print].
Babyak, M., Blumenthal, J. A., Her-
man, S., Khatri, P., Doraiswamy,
M., Moore, K., et al. (2000). Exer-
cise treatment for major depression:
maintenance of therapeutic benefit
at 10 months. Psychosom. Med. 62,
633–638.
Bachstetter, A. D., Morganti, J. M., Jern-
berg, J., Schlunk, A., Mitchell, S.
H., Brewster, K. W., et al. (2011).
Fractalkine and CX 3 CR1 regulate
hippocampal neurogenesis in adult
and aged rats. Neurobiol. Aging 32,
2030–2044.
Bansal, A. S., Bradley, A. S., Bishop, K.
N., Kiani-Alikhan, S., and Ford, B.
(2012). Chronic fatigue syndrome,
the immune system and viral infec-
tion. Brain Behav. Immun. 26, 24–31.
Barrientos, R. M., Frank, M. G., Crys-
dale, N. Y., Chapman, T. R., Ahrend-
sen, J. T., Day, H. E., et al. (2011).
Little exercise, big effects: revers-
ing aging and infection-induced
memory deficits, and underly-
ing processes. J. Neurosci. 31,
11578–11586.
Battista, D., Ferrari, C. C., Gage, F.
H., and Pitossi, F. J. (2006). Neuro-
genic niche modulation by activated
microglia: transforming growth fac-
tor beta increases neurogenesis in the
adult dentate gyrus. Eur. J. Neurosci.
23, 83–93.
Baune, B. T., Dannlowski, U., Dom-
schke, K., Janssen, D. G., Jordan,
M. A., Ohrmann, P., et al. (2010).
The interleukin 1 beta (IL1B)
gene is associated with failure to
achieve remission and impaired
emotion processing in major
depression. Biol. Psychiatry 67,
543–549.
Baune, B. T., and Eyre, H. (2012). Novel
perspectives on the role of immune
biomarkers in exercise and depres-
sion. Brain Behav. Immun. 26, 512.
Baune, B. T., Konrad, C., Grotegerd, D.,
Suslow, T., Birosova, E., Ohrmann,
P., et al. (2012a). Interleukin-6 gene
(IL-6): a possible role in brain mor-
phology in the healthy adult brain. J.
Neuroinflammation 9, 125.
Baune, B. T., Konrad, C., Grotegerd, D.,
Suslow, T., Ohrmann, P., Bauer, J., et
al. (2012b). Tumor necrosis factor
gene variation predicts hippocam-
pus volume in healthy individuals.
Biol. Psychiatry 72, 655–662.
Baune, B. T., Stuart, M., Gilmour, A.,
Wersching, H., Heindel, W., Arolt,
V., et al. (2012c). The relationship
between subtypes of depression and
cardiovascular disease: a systematic
review of biological models. Transl.
Psychiatry 2, e92.
Baune, B. T., Ponath, G., Rothermundt,
M., Riess, O., Funke, H., and Berger,
K. (2008a). Association between
genetic variants of IL-1beta, IL-6
and TNF-alpha cytokines and cog-
nitive performance in the elderly
general population of the MEMO-
study. Psychoneuroendocrinology 33,
68–76.
Baune, B. T., Wiede, F., Braun, A.,
Golledge, J., Arolt, V., and Koerner,
H. (2008b). Cognitive dysfunction
in mice deficient for TNF and its
receptors. Am. J. Med. Genet. B Neu-
ropsychiatr. Genet. 147B, 1056–1064.
Baune, B. T., and Thome, J. (2011).
Translational research approach to
biological and modifiable risk fac-
tors of psychosis and affective dis-
orders. World J. Biol. Psychiatry
12(Suppl 1), 28–34.
Beavers, K. M., Brinkley, T. E., and Nick-
las, B. J. (2010a). Effect of exercise
training on chronic inflammation.
Clin. Chim. Acta 411, 785–793.
Beavers, K. M., Hsu, F. C., Isom, S.,
Kritchevsky, S. B., Church, T., Good-
paster, B., et al. (2010b). Long-term
physical activity and inflammatory
biomarkers in older adults. Med. Sci.
Sports Exerc. 42, 2189–2196.
Beers, D. R., Henkel, J. S., Zhao, W.,
Wang, J., and Appel, S. H. (2008).
CD4+ T cells support glial neu-
roprotection, slow disease progres-
sion, and modify glial morphology
in an animal model of inherited
ALS. Proc. Natl. Acad. Sci. U.S.A. 105,
15558–15563.
Ben Menachem-Zidon, O., Avital,
A., Ben-Menahem, Y., Goshen,
I., Kreisel, T., Shmueli, E. M., et
al. (2011). Astrocytes support
hippocampal-dependent memory
and long-term potentiation via
interleukin-1 signaling. Brain Behav.
Immun. 25, 1008–1016.
Berk, M., and Jacka, F. (2012). Preven-
tive strategies in depression: gath-
ering evidence for risk factors and
potential interventions. Br. J. Psychi-
atry 201, 339–341.
Beumer, W., Gibney, S. M., Drex-
hage, R. C., Pont-Lezica, L., Door-
duin, J., Klein, H. C., et al. (2012).
The immune theory of psychiatric
diseases: a key role for activated
microglia and circulating mono-
cytes. J. Leukoc. Biol. 92, 959–975.
Bilbo, S. D., Smith, S. H., and Schwarz,
J. M. (2012). A lifespan approach
to neuroinflammatory and cognitive
disorders: a critical role for glia. J.
Neuroimmune Pharmacol. 7, 24–41.
Black, D. S., Cole, S. W., Irwin, M. R.,
Breen, E., St Cyr, N. M., Nazarian,
N., et al. (2012). Yogic meditation
reverses NF-kappaB and IRF-related
transcriptome dynamics in leuko-
cytes of family dementia caregivers
in a randomized controlled trial.
Psychoneuroendocrinology. doi:
10.1016/j.psyneuen.2012.06.011.
[Epub ahead of print].
Blume, J., Douglas, S. D., and Evans, D.
L. (2011). Immune suppression and
immune activation in depression.
Brain Behav. Immun. 25, 221–229.
Blumenthal, J. A., Babyak, M. A., Moore,
K. A., Craighead, W. E., Herman, S.,
Khatri, P., et al. (1999). Effects of
exercise training on older patients
with major depression. Arch. Intern.
Med. 159, 2349–2356.
Blumenthal, J. A., Babyak, M. A.,
O’Connor, C., Keteyian, S.,
Landzberg, J., Howlett, J., et al.
(2012a). Effects of exercise training
on depressive symptoms in patients
with chronic heart failure: the
HF-action randomized trial. JAMA
308, 465–474.
Blumenthal, J. A., Sherwood,A., Babyak,
M. A., Watkins, L. L., Smith, P. J.,
Hoffman, B. M., et al. (2012b). Exer-
cise and pharmacological treatment
of depressive symptoms in patients
with coronary heart disease: results
from the UPBEAT (understanding
the prognostic benefits of exercise
and antidepressant therapy) Study.
J. Am. Coll. Cardiol. 60, 1053–1063.
Bluthe, R. M., Castanon, N., Pousset, F.,
Bristow, A., Ball, C., Lestage, J., et
al. (1999). Central injection of IL-10
antagonizes the behavioural effects
of lipopolysaccharide in rats. Psy-
choneuroendocrinology 24, 301–311.
Bowen, K. K., Dempsey, R. J., and Vemu-
ganti, R. (2011). Adult interleukin-6
knockout mice show compromised
neurogenesis. Neuroreport 22,
126–130.
Bracchi-Ricard, V., Brambilla, R., Lev-
enson, J., Hu, W. H., Bramwell,
A., Sweatt, J. D., et al. (2008).
Astroglial nuclear factor-kappaB
regulates learning and memory and
synaptic plasticity in female mice. J.
Neurochem. 104, 611–623.
Bridle, C., Spanjers, K., Patel, S., Ather-
ton, N. M., and Lamb, S. E. (2012).
Effect of exercise on depression
severity in older people: systematic
review and meta-analysis of ran-
domised controlled trials. Br. J. Psy-
chiatry 201, 180–185.
Brynskikh, A., Warren, T., Zhu, J., and
Kipnis, J. (2008). Adaptive immunity
affects learning behavior in mice.
Brain Behav. Immun. 22, 861–869.
Butovsky, O., Koronyo-Hamaoui, M.,
Kunis, G., Ophir, E., Landa, G.,
Cohen, H., et al. (2006a). Glatiramer
acetate fights against Alzheimer’s
disease by inducing dendritic-like
microglia expressing insulin-like
growth factor 1. Proc. Natl. Acad. Sci.
U.S.A. 103, 11784–11789.
Butovsky, O., Ziv, Y., Schwartz, A.,
Landa, G., Talpalar, A. E., Pluchino,
S., et al. (2006b). Microglia acti-
vated by IL-4 or IFN-gamma
differentially induce neurogenesis
and oligodendrogenesis from adult
stem/progenitor cells. Mol. Cell.
Neurosci. 31, 149–160.
Butovsky, O., Kunis, G., Koronyo-
Hamaoui, M., and Schwartz, M.
(2007). Selective ablation of bone
marrow-derived dendritic cells
increases amyloid plaques in a
mouse Alzheimer’s disease model.
Eur. J. Neurosci. 26, 413–416.
Butovsky, O., Talpalar, A. E., Ben-
Yaakov, K., and Schwartz, M. (2005).
Activation of microglia by aggre-
gated beta-amyloid or lipopolysac-
charide impairs MHC-II expression
and renders them cytotoxic whereas
IFN-gamma and IL-4 render them
protective. Mol. Cell. Neurosci. 29,
381–393.
Butti, E., Bergami,A., Recchia,A., Bram-
billa, E., Del Carro, U., Amadio, S., et
al. (2008). IL4 gene delivery to the
CNS recruits regulatory T cells and
induces clinical recovery in mouse
models of multiple sclerosis. Gene
Ther. 15, 504–515.
Capuron, L., and Miller, A. H. (2011).
Immune system to brain sig-
naling: neuropsychopharmacologi-
cal implications. Pharmacol. Ther.
130, 226–238.
Cardon, M., Ron-Harel, N., Cohen, H.,
Lewitus, G. M., and Schwartz, M.
(2010). Dysregulation of kisspeptin
and neurogenesis at adolescence
Frontiers in Psychiatry | Affective Disorders and Psychosomatic Research February 2013 | Volume 4 | Article 3 | 22
Eyre et al. Neuroimmune effects of physical activity
link inborn immune deficits to the
late onset of abnormal sensorimo-
tor gating in congenital psycholog-
ical disorders. Mol. Psychiatry 15,
415–425.
Carlson, N. G., Wieggel, W. A., Chen,
J., Bacchi, A., Rogers, S. W., and
Gahring, L. C. (1999). Inflamma-
tory cytokines IL-1 alpha, IL-1 beta,
IL-6, and TNF-alpha impart neuro-
protection to an excitotoxin through
distinct pathways. J. Immunol. 163,
3963–3968.
Carmichael, M. D., Davis, J. M., Mur-
phy, E. A., Carson, J. A., Van
Rooijen, N., Mayer, E., et al.
(2010). Role of brain macrophages
on IL-1beta and fatigue following
eccentric exercise-induced muscle
damage. Brain Behav. Immun. 24,
564–568.
Chapoval, S., Dasgupta, P., Dorsey, N.
J., and Keegan, A. D. (2010). Reg-
ulation of the T helper cell type 2
(Th2)/T regulatory cell (Treg) bal-
ance by IL-4 and STAT6. J. Leukoc.
Biol. 87, 1011–1018.
Chiu, I. M., Chen, A., Zheng,Y., Kosaras,
B., Tsiftsoglou, S. A., Vartanian, T.
K., et al. (2008). T lymphocytes
potentiate endogenous neuropro-
tective inflammation in a mouse
model of ALS. Proc. Natl. Acad. Sci.
U.S.A. 105, 17913–17918.
Cohen, H., Ziv, Y., Cardon, M., Kaplan,
Z., Matar, M. A., Gidron, Y., et
al. (2006). Maladaptation to men-
tal stress mitigated by the adap-
tive immune system via depletion
of naturally occurring regulatory
CD4+CD25+ cells. J. Neurobiol. 66,
552–563.
Colbert, L. H., Visser, M., Simonsick,
E. M., Tracy, R. P., Newman, A. B.,
Kritchevsky, S. B., et al. (2004). Phys-
ical activity, exercise, and inflamma-
tory markers in older adults: findings
from the Health, Aging and Body
Composition Study. J. Am. Geriatr.
Soc. 52, 1098–1104.
Conboy, L., Varea, E., Castro, J. E.,
Sakouhi-Ouertatani, H., Calandra,
T., Lashuel, H. A., et al. (2011).
Macrophage migration inhibitory
factor is critically involved in basal
and fluoxetine-stimulated adult hip-
pocampal cell proliferation and in
anxiety, depression, and memory-
related behaviors. Mol. Psychiatry
16, 533–547.
Cordova, C., Lopes, E. S. F. Jr., Pires,
A. S., Souza, V. C., Brito, C. J.,
Moraes, C. F., et al. (2011). Long-
term resistance training is associated
with reduced circulating levels of IL-
6, IFN-gamma and TNF-alpha in
elderly women. Neuroimmunomod-
ulation 18, 165–170.
Corona, A. W., Huang, Y., O’Connor,
J. C., Dantzer, R., Kelley, K.
W., Popovich, P. G., et al.
(2010). Fractalkine receptor
(CX3CR1) deficiency sensitizes
mice to the behavioral changes
induced by lipopolysaccharide. J.
Neuroinflammation 7, 93.
Corona, A. W., Norden, D. M.,
Skendelas, J. P., Huang, Y.,
O’Connor, J. C., Lawson, M.,
et al. (2012). Indoleamine 2,3-
dioxygenase inhibition attenuates
lipopolysaccharide induced per-
sistent microglial activation and
depressive-like complications in
fractalkine receptor (CX(3)CR1)-
deficient mice. Brain Behav Immun.
doi:10.1016/j.bbi.2012.08.008.
[Epub ahead of print].
Costello, D. A., Lyons, A., Denieffe, S.,
Browne, T. C., Cox, F. F., and Lynch,
M. A. (2011). Long term potentia-
tion is impaired in membrane gly-
coprotein CD200-deficient mice: a
role for Toll-like receptor activation.
J. Biol. Chem. 286, 34722–34732.
Cox, F. F., Carney, D., Miller, A. M.,
and Lynch, M. A. (2012). CD200
fusion protein decreases microglial
activation in the hippocampus of
aged rats. Brain Behav. Immun. 26,
789–796.
Craft, L. (2005). Exercise and clinical
depression: examining two psycho-
logical mechanisms. Psychol. Sport.
Exerc. 6, 151–171.
Cuijpers, P., Beekman, A. T., and
Reynolds, C. F. III. (2012). Prevent-
ing depression: a global priority.
JAMA 307, 1033–1034.
Curtsinger, J. M., Schmidt, C. S.,
Mondino, A., Lins, D. C., Kedl, R. M.,
Jenkins, M. K., et al. (1999). Inflam-
matory cytokines provide a third sig-
nal for activation of naive CD4+
and CD8+ T cells. J. Immunol. 162,
3256–3262.
Dantzer, R., O’Connor, J. C., Freund,
G. G., Johnson, R. W., and Kelley,
K. W. (2008). From inflammation
to sickness and depression: when
the immune system subjugates the
brain. Nat. Rev. Neurosci. 9, 46–56.
Dantzer, R., O’Connor, J. C., Lawson,
M. A., and Kelley, K. W. (2011).
Inflammation-associated depres-
sion: from serotonin to kynurenine.
Psychoneuroendocrinology 36,
426–436.
Derecki, N. C., Cardani, A. N., Yang,
C. H., Quinnies, K. M., Crihfield,
A., Lynch, K. R., et al. (2010). Reg-
ulation of learning and memory by
meningeal immunity: a key role for
IL-4. J. Exp. Med. 207, 1067–1080.
Derecki, N. C., Quinnies, K. M., and
Kipnis, J. (2011). Alternatively
activated myeloid (M2) cells
enhance cognitive function in
immune compromised mice. Brain
Behav. Immun. 25, 379–385.
Deslandes, A. C., Moraes, H., Alves, H.,
Pompeu, F. A., Silveira, H., Mouta,
R., et al. (2010). Effect of aero-
bic training on EEG alpha asym-
metry and depressive symptoms
in the elderly: a 1-year follow-up
study. Braz. J. Med. Biol. Res. 43,
585–592.
Dhabhar, F. S., Burke, H. M., Epel, E. S.,
Mellon, S. H., Rosser, R., Reus, V. I.,
et al. (2009). Low serum IL-10 con-
centrations and loss of regulatory
association between IL-6 and IL-10
in adults with major depression. J.
Psychiatr. Res. 43, 962–969.
Diener, E. (1984). Subjective well-being.
Psychol. Bull. 94, 542–575.
Donges, C. E., Duffield, R., and
Drinkwater, E. J. (2010). Effects of
resistance or aerobic exercise train-
ing on interleukin-6, C-reactive pro-
tein, and body composition. Med.
Sci. Sports Exerc. 42, 304–313.
Dowlati, Y., Herrmann, N., Swardfager,
W., Liu, H., Sham, L., Reim, E. K.,
et al. (2010). A meta-analysis of
cytokines in major depression. Biol.
Psychiatry 67, 446–457.
Duman, C. H., Schlesinger, L., Ter-
williger, R., Russell, D. S., Newton, S.
S., and Duman, R. S. (2009). Periph-
eral insulin-like growth factor-I pro-
duces antidepressant-like behavior
and contributes to the effect of exer-
cise. Behav. Brain Res. 198, 366–371.
Ehninger, D., Wang, L. P., Klempin,
F., Romer, B., Kettenmann, H., and
Kempermann, G. (2011). Enriched
environment and physical activity
reduce microglia and influence the
fate of NG2 cells in the amygdala
of adult mice. Cell Tissue Res. 345,
69–86.
Ekdahl, C. T. (2012). Microglial activa-
tion – tuning and pruning adult neu-
rogenesis. Front. Pharmacol. 3:41.
doi:10.3389/fphar.2012.00041
Eller, T.,Vasar,V., Shlik, J., and Maron, E.
(2008). Pro-inflammatory cytokines
and treatment response to escitalo-
pram in major depressive disorder.
Prog. Neuropsychopharmacol. Biol.
Psychiatry 32, 445–450.
Erickson, K. I., Miller, D. L., and
Roecklein, K. A. (2012). The aging
hippocampus: interactions between
exercise, depression, and BDNF.
Neuroscientist 18, 82–97.
Erickson, K. I., Voss, M. W., Prakash, R.
S., Basak, C., Szabo, A., Chaddock,
L., et al. (2011). Exercise training
increases size of hippocampus and
improves memory. Proc. Natl. Acad.
Sci. U.S.A. 108, 3017–3022.
Eyre, H., and Baune, B. T. (2012a). Neu-
roimmunological effects of physical
exercise in depression. Brain Behav.
Immun. 26, 251–266.
Eyre, H., and Baune, B. T. (2012b). Neu-
roimmunomodulation in unipolar
depression: a focus on chronobi-
ology and chronotherapeutics. J.
Neural Transm. 119, 1147–1166.
Eyre, H., and Baune, B. T. (2012c).
Neuroplastic changes in depres-
sion: a role for the immune sys-
tem. Psychoneuroendocrinology 37,
1397–1416.
Foster, P. P., Rosenblatt, K. P., and Kuljis,
R. O. (2011). Exercise-induced cog-
nitive plasticity, implications for
mild cognitive impairment and
Alzheimer’s disease. Front. Neurol.
2:28. doi:10.3389/fneur.2011.00028
Fox, K. (2000). “The effects of exer-
cise on self-perceptions and self-
esteem,” in Physical Activity and
Psychological Well-Being, ed. F. K.
Biddle Sjh (London: Routledge),
88–117.
Frank, M. G., Baratta, M. V., Sprunger,
D. B., Watkins, L. R., and Maier,
S. F. (2007). Microglia serve as a
neuroimmune substrate for stress-
induced potentiation of CNS pro-
inflammatory cytokine responses.
Brain Behav. Immun. 21, 47–59.
Fujio, K., Okamura, T., and Yamamoto,
K. (2010). The Family of IL-
10-secreting CD4+ T cells. Adv.
Immunol. 105, 99–130.
Funk, J. A., Gohlke, J., Kraft, A. D.,
McPherson, C. A., Collins, J. B., and
Jean Harry, G. (2011). Voluntary
exercise protects hippocampal
neurons from trimethyltin injury:
possible role of interleukin-6 to
modulate tumor necrosis factor
receptor-mediated neurotoxicity.
Brain Behav. Immun. 25, 1063–1077.
Gallagher,P. J.,Castro,V.,Fava, M.,Weil-
burg, J. B., Murphy, S. N., Gainer,
V. S., et al. (2012). Antidepressant
response in patients with major
depression exposed to NSAIDs: a
pharmacovigilance study. Am. J. Psy-
chiatry 169, 1065–1072.
Garber, C. E., Blissmer, B., Deschenes,
M. R., Franklin, B. A., Lamonte, M.
J., Lee, I. M., et al. (2011). American
College of Sports Medicine position
stand. Quantity and quality of exer-
cise for developing and maintain-
ing cardiorespiratory, musculoskele-
tal, and neuromotor fitness in appar-
ently healthy adults: guidance for
prescribing exercise. Med. Sci. Sports
Exerc. 43, 1334–1359.
Garg, S. K., Banerjee, R., and Kipnis, J.
(2008). Neuroprotective immunity:
T cell-derived glutamate endows
astrocytes with a neuroprotective
www.frontiersin.org February 2013 | Volume 4 | Article 3 | 23
Eyre et al. Neuroimmune effects of physical activity
phenotype. J. Immunol. 180,
3866–3873.
Geffken, D. F., Cushman, M., Burke,
G. L., Polak, J. F., Sakkinen, P. A.,
and Tracy, R. P. (2001). Association
between physical activity and mark-
ers of inflammation in a healthy
elderly population. Am. J. Epidemiol.
153, 242–250.
Giunti, D., Parodi, B., Usai, C., Ver-
gani, L., Casazza, S., Bruzzone, S., et
al. (2012). Mesenchymal stem cells
shape microglia effector functions
through the release of CX3CL1. Stem
Cells 30, 2044–2053.
Gleeson, M., Bishop, N. C., Stensel,
D. J., Lindley, M. R., Mastana, S.
S., and Nimmo, M. A. (2011). The
anti-inflammatory effects of exer-
cise: mechanisms and implications
for the prevention and treatment
of disease. Nat. Rev. Immunol. 11,
607–615.
Godbout, K., Fenn, A., Huang, Y.,
and Gensel, J. (2012). Central
interleukin-4 infusion after a
peripheral lipopolysaccharide injec-
tion promotes a neuroprotective
CNS environment with increased
M2 microglia. Brain Behav. Immun.
26, S29–S30.
Hafner, S., Emeny, R. T., Lacruz, M. E.,
Baumert, J., Herder, C., Koenig, W.,
et al. (2011). Association between
social isolation and inflammatory
markers in depressed and non-
depressed individuals: results from
the MONICA/KORA study. Brain
Behav. Immun. 25, 1701–1707.
Hamer, M., Sabia, S., Batty, G. D.,
Shipley, M. J., Tabak, A. G., Singh-
Manoux, A., et al. (2012). Physi-
cal activity and inflammatory mark-
ers over 10 years: follow-up in men
and women from the Whitehall
II Cohort Study. Circulation 126,
928–933.
Hannestad, J., Dellagioia, N., and Bloch,
M. (2011). The effect of antidepres-
sant medication treatment on serum
levels of inflammatory cytokines: a
meta-analysis. Neuropsychopharma-
cology 36, 2452–2459.
Hannestad, J., Gallezot, J. D., Schaf-
bauer, T., Lim, K., Kloczynski,




sion tomography in nonhuman
primates. Neuroimage 63, 232–239.
Hashimoto, K. (2009). Emerging role of
glutamate in the pathophysiology of
major depressive disorder. Brain Res.
Rev. 61, 105–123.
Hauben, E., Butovsky, O., Nevo, U.,
Yoles, E., Moalem, G., Agranov,
E., et al. (2000). Passive or active
immunization with myelin basic
protein promotes recovery from
spinal cord contusion. J. Neurosci.
20, 6421–6430.
Hein, A. M., and O’Banion, M.
K. (2012). Neuroinflammation and
cognitive dysfunction in chronic dis-
ease and aging. J. Neuroimmune
Pharmacol. 7, 3–6.
Herring, A., Donath, A., Yarmolenko,
M., Uslar, E., Conzen, C., Kanakis,
D., et al. (2012). Exercise dur-
ing pregnancy mitigates Alzheimer-
like pathology in mouse offspring.
FASEB J. 26, 117–128.
Himmerich, H., Milenovic, S., Fulda,
S., Plumakers, B., Sheldrick, A. J.,
Michel, T. M., et al. (2010). Reg-
ulatory T cells increased while IL-
1beta decreased during antidepres-
sant therapy. J. Psychiatr. Res. 44,
1052–1057.
Hinwood, M., Morandini, J., Day, T.
A., and Walker, F. R. (2012). Evi-
dence that microglia mediate the
neurobiological effects of chronic
psychological stress on the Medial
prefrontal cortex. Cereb. Cortex 22,
1442–1454.
Hoffman, B. M., Blumenthal, J. A.,
Babyak, M. A., Smith, P. J., Rogers, S.
D., Doraiswamy, P. M., et al. (2008).
Exercise fails to improve neurocog-
nition in depressed middle-aged and
older adults. Med. Sci. Sports Exerc.
40, 1344–1352.
Irwin, M. R., and Olmstead, R. (2012).
Mitigating cellular inflammation in
older adults: a randomized con-
trolled trial of Tai Chi Chih. Am. J.
Geriatr. Psychiatry 20, 764–772.
Jenkins, M. K., and Johnson, J. G.
(1993). Molecules involved in T-cell
costimulation. Curr. Opin. Immunol.
5, 361–367.
Jeon, H., Mun, G. I., and Boo, Y.
C. (2012). Analysis of serum
cytokine/chemokine profiles
affected by aging and exercise in
mice. Cytokine 60, 487–492.
Kaneko, M., Stellwagen, D., Malenka,
R. C., and Stryker, M. P. (2008).
Tumor necrosis factor-alpha medi-
ates one component of competitive,
experience-dependent plasticity in
developing visual cortex. Neuron 58,
673–680.
Kessler, R. C., Berglund, P., Dem-
ler, O., Jin, R., Merikangas, K. R.,
and Walters, E. E. (2005). Lifetime
prevalence and age-of-onset distrib-
utions of DSM-IV disorders in the
National Comorbidity Survey Repli-
cation. Arch. Gen. Psychiatry 62,
593–602.
Kim, S. J., Lee, H., Joung, H. Y., Lee,
G., Lee, H. J., Shin, M. K., et al.
(2011). T-bet deficient mice exhibit
resistance to stress-induced develop-
ment of depression-like behaviors. J.
Neuroimmunol. 240–241, 45–51.
Kim, S. J., Lee, H., Lee, G., Oh,
S. J., Shin, M. K., Shim, I., et
al. (2012). CD4+CD25+ regula-
tory T cell depletion modulates
anxiety and depression-like behav-
iors in mice. PLoS ONE 7:e42054.
doi:10.1371/journal.pone.0042054
Kipnis, J., Avidan, H., Caspi, R. R., and
Schwartz, M. (2004a). Dual effect
of CD4+CD25+ regulatory T cells
in neurodegeneration: a dialogue
with microglia. Proc. Natl. Acad. Sci.
U.S.A. 101(Suppl 2), 14663–14669.
Kipnis, J., Cohen, H., Cardon, M., Ziv,
Y., and Schwartz, M. (2004b). T
cell deficiency leads to cognitive
dysfunction: implications for ther-
apeutic vaccination for schizophre-
nia and other psychiatric conditions.
Proc. Natl. Acad. Sci. U.S.A. 101,
8180–8185.
Kipnis, J., Derecki, N. C., Yang, C.,
and Scrable, H. (2008). Immu-
nity and cognition: what do age-
related dementia, HIV-dementia
and ‘chemo-brain’ have in common?
Trends Immunol. 29, 455–463.
Knochel, C., Oertel-Knochel, V.,
O’Dwyer, L., Prvulovic, D., Alves,
G., Kollmann, B., et al. (2012).
Cognitive and behavioural effects
of physical exercise in psychiatric
patients. Prog. Neurobiol. 96, 46–68.
Kohl, H. W. III, Craig, C. L., Lambert,
E. V., Inoue, S., Alkandari, J. R., Lee-
tongin, G., et al. (2012). The pan-
demic of physical inactivity: global
action for public health. Lancet 380,
294–305.
Kohm, A. P., McMahon, J. S., Podo-
jil, J. R., Begolka, W. S., Degutes,
M., Kasprowicz, D. J., et al. (2006).
Cutting edge: anti-CD25 mono-
clonal antibody injection results
in the functional inactivation, not
depletion, of CD4+CD25+ T reg-
ulatory cells. J. Immunol. 176,
3301–3305.
Kohman, R. A., Deyoung, E. K., Bhat-
tacharya, T. K., Peterson, L. N., and
Rhodes, J. S. (2012). Wheel run-
ning attenuates microglia prolifer-
ation and increases expression of
a proneurogenic phenotype in the
hippocampus of aged mice. Brain
Behav. Immun. 26, 803–810.
Kohut, M. L., McCann, D. A., Russell, D.
W., Konopka, D. N., Cunnick, J. E.,
Franke, W. D., et al. (2006). Aerobic
exercise,but not flexibility/resistance
exercise, reduces serum IL-18, CRP,
and IL-6 independent of beta-
blockers, BMI, and psychosocial fac-
tors in older adults. Brain Behav.
Immun. 20, 201–209.
Kokaia, Z., Martino, G., Schwartz, M.,
and Lindvall, O. (2012). Cross-
talk between neural stem cells and
immune cells: the key to better brain
repair? Nat. Neurosci. 15, 1078–1087.
Koronyo-Hamaoui, M., Ko, M. K.,
Koronyo, Y., Azoulay, D., Seksenyan,
A., Kunis, G., et al. (2009). Atten-
uation of AD-like neuropathology
by harnessing peripheral immune
cells: local elevation of IL-10
and MMP-9. J. Neurochem. 111,
1409–1424.
Latimer, C. S., Searcy, J. L., Bridges,
M. T., Brewer, L. D., Popovic,
J., Blalock, E. M., et al. (2011).
Reversal of glial and neurovas-
cular markers of unhealthy brain
aging by exercise in middle-aged
female mice. PLoS ONE 6:e26812.
doi:10.1371/journal.pone.0026812
Lautenschlager, N. T., Cox, K., and
Cyarto, E. V. (2012). The influence of
exercise on brain aging and demen-
tia. Biochim. Biophys. Acta 1822,
474–481.
Lavretsky, H., Alstein, L. L., Olmstead,
R. E., Ercoli, L. M., Riparetti-Brown,
M., Cyr, N. S., et al. (2011). Com-
plementary use of Tai Chi Chih
augments escitalopram treatment of
geriatric depression: a randomized
controlled trial. Am. J. Geriatr. Psy-
chiatry 19, 839–850.
Lee, H. B., and Lyketsos, C. G. (2003).
Depression in Alzheimer’s disease:
heterogeneity and related issues.
Biol. Psychiatry 54, 353–362.
Lee, I. M., Shiroma, E. J., Lobelo, F.,
Puska, P., Blair, S. N., and Katz-
marzyk, P. T. (2012). Effect of
physical inactivity on major non-
communicable diseases worldwide:
an analysis of burden of disease
and life expectancy. Lancet 380,
219–229.
Leem, Y. H., Lee, Y. I., Son, H. J., and
Lee, S. H. (2011). Chronic exer-
cise ameliorates the neuroinflamma-
tion in mice carrying NSE/htau23.
Biochem. Biophys. Res. Commun.
406, 359–365.
Leonard, B., and Maes, M. (2012).
Mechanistic explanations how
cell-mediated immune activation,
inflammation and oxidative and
nitrosative stress pathways and their
sequels and concomitants play a role
in the pathophysiology of unipolar
depression. Neurosci. Biobehav. Rev.
36, 764–785.
Lepore, S. J. (1997). Expressive writ-
ing moderates the relation between
intrusive thoughts and depressive
symptoms. J. Pers. Soc. Psychol. 73,
1030–1037.
Lewitus, G. M., Cohen, H., and
Schwartz, M. (2008). Reducing
Frontiers in Psychiatry | Affective Disorders and Psychosomatic Research February 2013 | Volume 4 | Article 3 | 24
Eyre et al. Neuroimmune effects of physical activity
post-traumatic anxiety by immu-
nization. Brain Behav. Immun. 22,
1108–1114.
Li, Y., Xiao, B., Qiu, W., Yang, L., Hu,
B., Tian, X., et al. (2010). Altered
expression of CD4+CD25+ regula-
tory T cells and its 5-HT(1a) recep-
tor in patients with major depression
disorder. J. Affect. Disord. 124, 68–75.
Libardi, C. A., De Souza, G. V.,
Cavaglieri, C. R., Madruga,V. A., and
Chacon-Mikahil, M. P. (2012). Effect
of resistance, endurance, and con-
current training on TNF-alpha, IL-6,
and CRP. Med. Sci. Sports Exerc. 44,
50–56.
Littrell, J. L. (2012). Taking the
perspective that a depressive
state reflects inflammation:
implications for the use of anti-
depressants. Front. Psychol. 3:297.
doi:10.3389/fpsyg.2012.00297
Liu, D., Wang, Z., Liu, S., Wang,
F., Zhao, S., and Hao, A. (2011).
Anti-inflammatory effects of flu-
oxetine in lipopolysaccharide(LPS)-
stimulated microglial cells. Neu-
ropharmacology 61, 592–599.
Lyons, A., Downer, E. J., Crotty, S.,
Nolan,Y. M., Mills, K. H., and Lynch,
M. A. (2007). CD200 ligand recep-
tor interaction modulates microglial
activation in vivo and in vitro: a role
for IL-4. J. Neurosci. 27, 8309–8313.
Lyons, A., McQuillan, K., Deighan, B. F.,
O’Reilly, J. A., Downer, E. J., Mur-
phy, A. C., et al. (2009). Decreased
neuronal CD200 expression in IL-
4-deficient mice results in increased
neuroinflammation in response to
lipopolysaccharide. Brain Behav.
Immun. 23, 1020–1027.
Maes, M. (2011). Depression is an
inflammatory disease, but cell-
mediated immune activation is the
key component of depression. Prog.
Neuropsychopharmacol. Biol. Psychi-
atry 35, 664–675.
Mahendra, N., and Arkin, S. (2003).
Effects of four years of exercise, lan-
guage, and social interventions on
Alzheimer discourse. J. Commun.
Disord. 36, 395–422.
Marosi, K., Bori, Z., Hart, N., Sarga,
L., Koltai, E., Radak, Z., et al.
(2012). Long-term exercise treat-
ment reduces oxidative stress in the
hippocampus of aging rats. Neuro-
science 226, 21–28.
Martino, G., Pluchino, S., Bonfanti,
L., and Schwartz, M. (2011). Brain
regeneration in physiology and
pathology: the immune signature
driving therapeutic plasticity of
neural stem cells. Physiol. Rev. 91,
1281–1304.
Martins, R. A., Neves, A. P., Coelho-
Silva, M. J., Verissimo, M. T., and
Teixeira, A. M. (2010). The effect of
aerobic versus strength-based train-
ing on high-sensitivity C-reactive
protein in older adults. Eur. J. Appl.
Physiol. 110, 161–169.
Mathieu, P., Piantanida, A. P., and
Pitossi, F. (2010). Chronic expres-
sion of transforming growth factor-
beta enhances adult neurogene-
sis. Neuroimmunomodulation 17,
200–201.
Matthys, P., Mitera, T., Heremans,
H., Van Damme, J., and Billiau,
A. (1995). Anti-gamma interferon
and anti-interleukin-6 antibodies
affect staphylococcal enterotoxin
B-induced weight loss, hypo-
glycemia, and cytokine release in
D-galactosamine-sensitized and
unsensitized mice. Infect. Immun.
63, 1158–1164.
McAfoose, J., and Baune, B. T. (2009).
Evidence for a cytokine model of
cognitive function. Neurosci. Biobe-
hav. Rev. 33, 355–366.
McNally,L.,Bhagwagar,Z., and Hannes-
tad, J. (2008). Inflammation, glu-
tamate, and glia in depression: a
literature review. CNS Spectr. 13,
501–510.
Mead, G. E., Morley, W., Campbell,
P., Greig, C. A., McMurdo, M.,
and Lawlor, D. A. (2008). Exer-
cise for depression. Cochrane Data-
base Syst. Rev. 4, CD004366. doi:
10.1002/14651858.CD004366.pub3
Mesquita, A. R., Correia-Neves, M.,
Roque, S., Castro, A. G., Vieira,
P., Pedrosa, J., et al. (2008). IL-10
modulates depressive-like behavior.
J. Psychiatr. Res. 43, 89–97.
Miller, A. H. (2010). Depression and
immunity: a role for T cells? Brain
Behav. Immun. 24, 1–8.
Miller, A. H., Maletic, V., and Raison, C.
L. (2009). Inflammation and its dis-
contents: the role of cytokines in the
pathophysiology of major depres-
sion. Biol. Psychiatry 65, 732–741.
Mitschelen, M., Yan, H., Farley, J. A.,
Warrington, J. P., Han, S., Herenu,
C. B., et al. (2011). Long-term
deficiency of circulating and hip-
pocampal insulin-like growth fac-
tor I induces depressive behavior in
adult mice: a potential model of geri-
atric depression. Neuroscience 185,
50–60.
Mizuhara, H., O’Neill, E., Seki, N.,
Ogawa, T., Kusunoki, C., Otsuka,
K., et al. (1994). T cell activation-
associated hepatic injury: mediation
by tumor necrosis factors and pro-
tection by interleukin 6. J. Exp. Med.
179, 1529–1537.
Moon, H. Y., Kim, S. H., Yang, Y. R.,
Song, P., Yu, H. S., Park, H. G., et
al. (2012). Macrophage migration
inhibitory factor mediates the anti-
depressant actions of voluntary exer-
cise. Proc. Natl. Acad. Sci. U.S.A. 109,
13094–13099.
Moon, M. L., McNeil, L. K., and Fre-
und, G. G. (2011). Macrophages
make me sick: how macrophage
activation states influence sickness
behavior. Psychoneuroendocrinology
36, 1431–1440.
Moron, J. A., Zakharova, I., Ferrer, J.
V., Merrill, G. A., Hope, B., Lafer, E.
M., et al. (2003). Mitogen-activated
protein kinase regulates dopamine
transporter surface expression and
dopamine transport capacity. J. Neu-
rosci. 23, 8480–8488.
Moylan, S., Maes, M., Wray, N. R., and
Berk, M. (2012). The neuroprogres-
sive nature of major depressive dis-
order: pathways to disease evolu-
tion and resistance, and therapeu-
tic implications. Mol. Psychiatry. doi:
10.1038/mp.2012.33. [Epub ahead
of print].
Muller, N., Myint, A. M., and Schwarz,
M. J. (2011). Inflammatory bio-
markers and depression. Neurotox.
Res. 19, 308–318.
Musil, R., Schwarz, M. J., Riedel, M.,
Dehning, S., Cerovecki, A., Spell-
mann, I., et al. (2011). Elevated
macrophage migration inhibitory
factor and decreased transforming
growth factor-beta levels in major
depression – no influence of cele-
coxib treatment. J. Affect. Disord.
134, 217–225.
Myint,A. M., Leonard, B. E., Steinbusch,
H. W., and Kim, Y. K. (2005). Th1,
Th2, and Th3 cytokine alterations in
major depression. J. Affect. Disord.
88, 167–173.
Nakajima, A., Yamada, K., Nagai,
T., Uchiyama, T., Miyamoto, Y.,
Mamiya, T., et al. (2004). Role
of tumor necrosis factor-alpha
in methamphetamine-induced drug
dependence and neurotoxicity. J.
Neurosci. 24, 2212–2225.
Nguyen, K., D’Mello, C., Le, T.,
Urbanski, S., and Swain, M. G.
(2012). Regulatory T cells sup-
press sickness behaviour develop-
ment without altering liver injury
in cholestatic mice. J. Hepatol. 56,
626–631.
Nichol, K. E., Poon, W. W., Parachikova,
A. I., Cribbs, D. H., Glabe, C. G.,
and Cotman, C. W. (2008). Exercise
alters the immune profile in Tg2576
Alzheimer mice toward a response
coincident with improved cogni-
tive performance and decreased
amyloid. J. Neuroinflammation
5, 13.
Nicklas, B. J., Hsu, F. C., Brinkley, T.
J., Church, T., Goodpaster, B. H.,
Kritchevsky, S. B., et al. (2008).
Exercise training and plasma C-
reactive protein and interleukin-6 in
elderly people. J. Am. Geriatr. Soc. 56,
2045–2052.
Nybo, L., Nielsen, B., Pedersen, B.
K., Moller, K., and Secher, N. H.
(2002). Interleukin-6 release from
the human brain during prolonged
exercise. J. Physiol. (Lond.) 542,
991–995.
Ojo, B., Rezaie, P., Gabbott, P. L., Davies,
H., Colyer, F., Cowley, T. R., et
al. (2012). Age-related changes in
the hippocampus (loss of synap-
tophysin and glial-synaptic interac-
tion) are modified by systemic treat-
ment with an NCAM-derived pep-
tide, FGL. Brain Behav. Immun. 26,
778–788.
Olah, M., Ping, G., De Haas, A. H.,
Brouwer, N., Meerlo, P., Van Der
Zee, E. A., et al. (2009). Enhanced
hippocampal neurogenesis in the
absence of microglia T cell interac-
tion and microglia activation in the
murine running wheel model. Glia
57, 1046–1061.
Park, S. E., Dantzer, R., Kelley, K.
W., and McCusker, R. H. (2011a).
Central administration of insulin-
like growth factor-I decreases
depressive-like behavior and brain
cytokine expression in mice. J.
Neuroinflammation 8, 12.
Park, S. E., Lawson, M., Dantzer,
R., Kelley, K. W., and McCusker,
R. H. (2011b). Insulin-like growth
factor-I peptides act centrally to
decrease depression-like behavior of
mice treated intraperitoneally with
lipopolysaccharide. J. Neuroinflam-
mation 8, 179.
Pasco, J. A., Jacka, F. N., Williams, L. J.,
Brennan, S. L., Leslie, E., and Berk,
M. (2011a). Don’t worry, be active:
positive affect and habitual physical
activity. Aust. N. Z. J. Psychiatry 45,
1047–1052.
Pasco, J. A., Williams, L. J., Jacka, F.
N., Henry, M. J., Coulson, C. E.,
Brennan, S. L., et al. (2011b). Habit-
ual physical activity and the risk
for depressive and anxiety disorders
among older men and women. Int.
Psychogeriatr. 23, 292–298.
Pereira, A. C., Huddleston, D. E., Brick-
man, A. M., Sosunov, A. A., Hen, R.,
McKhann, G. M., et al. (2007). An
in vivo correlate of exercise-induced
neurogenesis in the adult dentate
gyrus. Proc. Natl. Acad. Sci. U.S.A.
104, 5638–5643.
Ponomarev, E. D., Veremeyko, T., and
Weiner, H. L. (2012). MicroRNAs
are universal regulators of differen-
tiation, activation, and polarization
of microglia and macrophages in
www.frontiersin.org February 2013 | Volume 4 | Article 3 | 25
Eyre et al. Neuroimmune effects of physical activity
normal and diseased CNS. Glia 61,
91–103.
Popoli, M., Yan, Z., McEwen, B. S., and
Sanacora, G. (2012). The stressed
synapse: the impact of stress and glu-
cocorticoids on glutamate transmis-
sion. Nat. Rev. Neurosci. 13, 22–37.
Prinz, M., Priller, J., Sisodia, S. S., and
Ransohoff, R. M. (2011). Hetero-
geneity of CNS myeloid cells and
their roles in neurodegeneration.
Nat. Neurosci. 14, 1227–1235.
Quan, N., and Banks, W. A. (2007).
Brain-immune communication
pathways. Brain Behav. Immun. 21,
727–735.
Raison, C. L., and Miller, A. H. (2011).
Is depression an inflammatory dis-
order? Curr. Psychiatry Rep. 13,
467–475.
Raison, C. L., Rutherford, R. E., Wool-
wine, B. J., Shuo, C., Schettler, P.,
Drake, D. F., et al. (2012). A random-
ized controlled trial of the tumor
necrosis factor antagonist infliximab
for treatment-resistant depression:
the role of baseline inflammatory
biomarkers. Arch. Gen. Psychiatry.
doi: 10.1001/2013.jamapsychiatry.4.
[Epub ahead of print].
Ransohoff, R. M., Kivisakk, P., and Kidd,
G. (2003). Three or more routes for
leukocyte migration into the central
nervous system. Nat. Rev. Immunol.
3, 569–581.
Rasmussen, P., Vedel, J. C., Olesen, J.,
Adser, H., Pedersen, M. V., Hart, E., et
al. (2011). In humans IL-6 is released
from the brain during and after exer-
cise and paralleled by enhanced IL-6
mRNA expression in the hippocam-
pus of mice. Acta Physiol. (Oxf.) 201,
475–482.
Rethorst, C. D., Moynihan, J., Lyness,
J. M., Heffner, K. L., and Chapman,
B. P. (2011). Moderating effects of
moderate-intensity physical activity
in the relationship between depres-
sive symptoms and interleukin-6 in
primary care patients. Psychosom.
Med. 73, 265–269.
Rethorst, C. D., Toups, M. S., Greer,
T. L., Nakonezny, P. A., Car-
mody, T. J., Grannemann, B. D.,
et al. (2012). Pro-inflammatory
cytokines as predictors of antide-
pressant effects of exercise in major
depressive disorder. Mol. Psychiatry.
doi: 10.1038/mp.2012.125. [Epub
ahead of print].
Rethorst, C. D., Wipfli, B. M., and
Landers, D. M. (2009). The antide-
pressive effects of exercise: a meta-
analysis of randomized trials. Sports
Med. 39, 491–511.
Reuben, D. B., Judd-Hamilton, L., Har-
ris, T. B., and Seeman, T. E. (2003).
The associations between physical
activity and inflammatory mark-
ers in high-functioning older per-
sons: MacArthur Studies of Success-
ful Aging. J. Am. Geriatr. Soc. 51,
1125–1130.
Rimer, J., Dwan, K., Lawlor, D. A., Greig,
C. A., McMurdo, M., Morley, W.,
et al. (2012). Exercise for depres-
sion. Cochrane Database Syst. Rev. 7,
CD004366.
Rogers, J. T., Morganti, J. M., Bach-
stetter, A. D., Hudson, C. E., Peters,
M. M., Grimmig, B. A., et al.
(2011). CX3CR1 deficiency leads to
impairment of hippocampal cogni-
tive function and synaptic plasticity.
J. Neurosci. 31, 16241–16250.
Rolls, A., Schori, H., London, A., and
Schwartz, M. (2008). Decrease in
hippocampal neurogenesis during
pregnancy: a link to immunity. Mol.
Psychiatry 13, 468–469.
Ron-Harel, N., Cardon, M., and
Schwartz, M. (2011). Brain home-
ostasis is maintained by “danger”
signals stimulating a supportive
immune response within the brain’s
borders. Brain Behav. Immun. 25,
1036–1043.
Rook, G. A., Lowry, C. A., and Raison,
C. L. (2011). Lymphocytes in neu-
roprotection, cognition and emo-
tion: is intolerance really the answer?
Brain Behav. Immun. 25, 591–601.
Rush, A. J., Trivedi, M. H., Wisniewski,
S. R., Nierenberg, A. A., Stewart,
J. W., Warden, D., et al. (2006a).
Acute and longer-term outcomes in
depressed outpatients requiring one
or several treatment steps: a STAR∗D
report. Am. J. Psychiatry 163,
1905–1917.
Rush, A. J., Trivedi, M. H., Wis-
niewski, S. R., Stewart, J. W., Nieren-
berg, A. A., Thase, M. E., et al.
(2006b). Bupropion-SR, sertraline,
or venlafaxine-XR after failure of
SSRIs for depression. N. Engl. J. Med.
354, 1231–1242.
Salmon, P. (2001). Effects of physi-
cal exercise on anxiety, depression,
and sensitivity to stress: a unify-
ing theory. Clin. Psychol. Rev. 21,
33–61.
Santello, M., and Volterra, A. (2012).
TNFalpha in synaptic function:
switching gears. Trends Neurosci. 35,
638–647.
Santos, R. V., Viana, V. A., Boscolo, R.
A., Marques, V. G., Santana, M. G.,
Lira, F. S., et al. (2012). Moderate
exercise training modulates cytokine
profile and sleep in elderly people.
Cytokine 60, 731–735.
Sarris, J., Moylan, S., Camfield, D. A.,
Pase,M. P.,Mischoulon,D.,Berk,M.,
et al. (2012). Complementary med-
icine, exercise, meditation, diet, and
lifestyle modification for anxiety dis-
orders: a review of current evidence.
Evid. Based Complement. Alternat.
Med. 2012, 809653.
Schwartz, M., Butovsky, O., Bruck,
W., and Hanisch, U. K. (2006).
Microglial phenotype: is the com-
mitment reversible? Trends Neurosci.
29, 68–74.
Schwartz, M., and Shechter, R. (2010a).
Protective autoimmunity functions
by intracranial immunosurveil-
lance to support the mind: the
missing link between health
and disease. Mol. Psychiatry 15,
342–354.
Schwartz, M., and Shechter, R. (2010b).
Systemic inflammatory cells fight off
neurodegenerative disease. Nat. Rev.
Neurol. 6, 405–410.
Schwarz, J. M., and Bilbo, S. D. (2011).
“The immune system and the devel-
oping brain,” in Colloquium Series
on the Developing Brain, Vol. 2, No.
3, ed. M. M. McCarthy (San Rafael:
Morgan and Claypool Publishers),
1–128.
Schwarz, J. M., and Bilbo, S. D. (2012).
Sex, glia, and development: interac-
tions in health and disease. Horm.
Behav. 62, 243–253.
Shaked, I., Tchoresh, D., Gersner, R.,
Meiri, G., Mordechai, S., Xiao, X., et
al. (2005). Protective autoimmunity:
interferon-gamma enables microglia
to remove glutamate without evok-
ing inflammatory mediators. J. Neu-
rochem. 92, 997–1009.
Shechter, R., London, A., Varol, C.,
Raposo, C., Cusimano, M., Yovel,
G., et al. (2009). Infiltrating blood-
derived macrophages are vital cells
playing an anti-inflammatory role
in recovery from spinal cord injury
in mice. PLoS Med. 6:e1000113.
doi:10.1371/journal.pmed.1000113
Sherry, C. L., Kim, S. S., Dilger, R. N.,
Bauer, L. L., Moon, M. L., Tapping,
R. I., et al. (2010). Sickness behavior
induced by endotoxin can be mit-
igated by the dietary soluble fiber,
pectin, through up-regulation of IL-
4 and Th2 polarization. Brain Behav.
Immun. 24, 631–640.
Shimizu, E., Kawahara, K., Kajizono,
M., Sawada, M., and Nakayama, H.
(2008). IL-4-induced selective clear-
ance of oligomeric beta-amyloid
peptide(1–42) by rat primary type
2 microglia. J. Immunol. 181,
6503–6513.
Sigwalt, A. R., Budde, H., Helmich,
I., Glaser, V., Ghisoni, K., Lanza,
S., et al. (2011). Molecular aspects
involved in swimming exercise train-
ing reducing anhedonia in a rat
model of depression. Neuroscience
192, 661–674.
Smith, P. J., Blumenthal, J. A., Hoff-
man, B. M., Cooper, H., Strauman, T.
A., Welsh-Bohmer, K., et al. (2010).
Aerobic exercise and neurocognitive
performance: a meta-analytic review
of randomized controlled trials. Psy-
chosom. Med. 72, 239–252.
Southwick, S. M., and Charney, D. S.
(2012). The science of resilience:
implications for the prevention and
treatment of depression. Science 338,
79–82.
Starkie, R., Ostrowski, S. R., Jauf-
fred, S., Febbraio, M., and Peder-
sen, B. K. (2003). Exercise and IL-6
infusion inhibit endotoxin-induced
TNF-alpha production in humans.
FASEB J. 17, 884–886.
Stellwagen, D., and Malenka, R. C.
(2006). Synaptic scaling mediated
by glial TNF-alpha. Nature 440,
1054–1059.
Stewart, L. K., Flynn, M. G., Camp-
bell, W. W., Craig, B. A., Robinson, J.
P., Timmerman, K. L., et al. (2007).
The influence of exercise training
on inflammatory cytokines and C-
reactive protein. Med. Sci. Sports
Exerc. 39, 1714–1719.
Stuart, M. J., and Baune, B. T.
(2012). Depression and type 2
diabetes: inflammatory mechanisms
of a psychoneuroendocrine co-
morbidity. Neurosci. Biobehav. Rev.
36, 658–676.
Sutcigil, L., Oktenli, C., Musabak, U.,
Bozkurt, A., Cansever, A., Uzun,
O., et al. (2007). Pro- and anti-
inflammatory cytokine balance in
major depression: effect of sertraline
therapy. Clin. Dev. Immunol. 2007,
76396.
Trejo, J. L., Piriz, J., Llorens-Martin,
M. V., Fernandez, A. M., Bolos, M.,
Leroith, D., et al. (2007). Central
actions of liver-derived insulin-like
growth factor I underlying its pro-
cognitive effects. Mol. Psychiatry 12,
1118–1128.
Trivedi, M. H., Greer, T. L., Church, T. S.,
Carmody, T. J., Grannemann, B. D.,
Galper, D. I., et al. (2011). Exercise
as an augmentation treatment for
nonremitted major depressive dis-
order: a randomized, parallel dose
comparison. J. Clin. Psychiatry 72,
677–684.
Trivedi, M. H., Rush, A. J., Wisniewski,
S. R., Nierenberg, A. A., Warden,
D., Ritz, L., et al. (2006). Evalua-
tion of outcomes with citalopram
for depression using measurement-
based care in STAR∗D: implications
for clinical practice. Am. J. Psychiatry
163, 28–40.
Tse, H. M., Milton, M. J., Schreiner,
S., Profozich, J. L., Trucco, M., and
Piganelli, J. D. (2007). Disruption of
Frontiers in Psychiatry | Affective Disorders and Psychosomatic Research February 2013 | Volume 4 | Article 3 | 26
Eyre et al. Neuroimmune effects of physical activity
innate-mediated proinflammatory
cytokine and reactive oxygen species
third signal leads to antigen-specific
hyporesponsiveness. J. Immunol.
178, 908–917.
Vukovic, J., Colditz, M. J., Blackmore, D.
G., Ruitenberg, M. J., and Bartlett, P.
F. (2012). Microglia modulate hip-
pocampal neural precursor activity
in response to exercise and aging. J.
Neurosci. 32, 6435–6443.
Walker, F. R. (2012). A review of the
mechanism of action for selective
serotonin reuptake inhibitors:
do these drugs possess anti-
inflammatory properties and is
this relevant in the treatment of
depression? Neuropharmacology
67C, 304–317.
Walker, P. A., Letourneau, P. A., Bedi, S.,
Shah,S. K., Jimenez,F., and Cox,C. S.
Jr (2011). Progenitor cells as remote
“bioreactors”: neuroprotection via
modulation of the systemic inflam-
matory response. World J. Stem Cells
3, 9–18.
Walsh, J. T., and Kipnis, J. (2011). Regu-
latory T cells in CNS injury: the sim-
ple, the complex and the confused.
Trends. Mol. Med. 17, 541–547.
Walton, N. M., Sutter, B. M., Lay-
well, E. D., Levkoff, L. H., Kearns,
S. M., Marshall, G. P. II, et al.
(2006). Microglia instruct subven-
tricular zone neurogenesis. Glia 54,
815–825.
Warner-Schmidt, J. L., Vanover, K.
E., Chen, E. Y., Marshall, J. J.,
and Greengard, P. (2011). Antide-
pressant effects of selective sero-
tonin reuptake inhibitors (SSRIs)
are attenuated by antiinflamma-
tory drugs in mice and humans.
Proc. Natl. Acad. Sci. U.S.A. 108,
9262–9267.
WHO. (2008). Global Burden of Disease:
2004 Update. Geneva: WHO.
Wong, M. L., Dong, C., Maestre-Mesa,
J., and Licinio, J. (2008). Poly-
morphisms in inflammation-related
genes are associated with suscepti-
bility to major depression and anti-
depressant response. Mol. Psychiatry
13, 800–812.
Wu, M. D., Hein, A. M., Moravan,
M. J., Shaftel, S. S., Olschowka, J.
A., and O’Banion, M. K. (2012).
Adult murine hippocampal neuro-
genesis is inhibited by sustained IL-
1beta and not rescued by voluntary
running. Brain Behav. Immun. 26,
292–300.
Yi, C. X., Al-Massadi, O., Donelan, E.,
Lehti, M., Weber, J., Ress, C., et
al. (2012). Exercise protects against
high-fat diet-induced hypothalamic
inflammation. Physiol. Behav. 106,
485–490.
Yirmiya, R., and Goshen, I. (2011).
Immune modulation of learn-
ing, memory, neural plasticity and
neurogenesis. Brain Behav. Immun.
25, 181–213.
Zhou, X., Bailey-Bucktrout, S., Jeker, L.
T., and Bluestone, J. A. (2009). Plas-
ticity of CD4+ FoxP3+ T cells. Curr.
Opin. Immunol. 21, 281–285.
Zhu, C. B., Blakely, R. D., and Hewlett,
W. A. (2006). The proinflamma-
tory cytokines interleukin-1beta and
tumor necrosis factor-alpha activate
serotonin transporters. Neuropsy-
chopharmacology 31, 2121–2131.
Ziv, Y., Ron, N., Butovsky, O., Landa,
G., Sudai, E., Greenberg, N., et
al. (2006). Immune cells contribute
to the maintenance of neuroge-
nesis and spatial learning abili-
ties in adulthood. Nat. Neurosci. 9,
268–275.
Conflict of Interest Statement: The
authors declare that the research was
conducted in the absence of any com-
mercial or financial relationships that
could be construed as a potential con-
flict of interest.
Received: 30 November 2012; paper
pending published: 25 December 2012;
accepted: 07 January 2013; published
online: 04 February 2013.
Citation: Eyre HA, Papps E and
Baune BT (2013) Treating depres-
sion and depression-like behavior with
physical activity: an immune per-
spective. Front. Psychiatry 4:3. doi:
10.3389/fpsyt.2013.00003
This article was submitted to Frontiers
in Affective Disorders and Psychosomatic
Research, a specialty of Frontiers in Psy-
chiatry.
Copyright © 2013 Eyre, Papps and
Baune. This is an open-access article dis-
tributed under the terms of the Creative
Commons Attribution License, which
permits use, distribution and reproduc-
tion in other forums, provided the original
authors and source are credited and sub-
ject to any copyright notices concerning
any third-party graphics etc.
www.frontiersin.org February 2013 | Volume 4 | Article 3 | 27
